[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 582
1. Kovács K, Varnai AD, Bollmann M, Bankfalvi A, Szendy M, Speich N, Schmitt C, Pajor L, Bollmann R: Prevalence and genotype distribution of multiple human papillomavirus infection in the uterine cervix: a 7.5-year longitudinal study in a routine cytology-based screening population in West Germany. J Med Virol; 2008 Oct;80(10):1814-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and genotype distribution of multiple human papillomavirus infection in the uterine cervix: a 7.5-year longitudinal study in a routine cytology-based screening population in West Germany.
  • In the present study, the prevalence and type-specific composition of multiple HPV infections were investigated in a routine cervical screening population in West Germany both at a cross-sectional level and longitudinally.
  • [MeSH-major] Cervix Uteri / virology. Papillomaviridae / genetics. Papillomavirus Infections / epidemiology. Papillomavirus Infections / virology. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma / virology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. Cohort Studies. Cross-Sectional Studies. DNA, Viral / analysis. Female. Germany, West / epidemiology. Humans. Longitudinal Studies. Mass Screening. Middle Aged. Polymerase Chain Reaction. Prevalence. Vaginal Smears


2. Massad LS, Xie X, Darragh TM, Minkoff H, Levine AM, D'Souza G, Cajigas A, Colie C, Watts DH, Strickler HD: Histologic correlates of glandular abnormalities in cervical cytology among women with human immunodeficiency virus. Obstet Gynecol; 2009 Nov;114(5):1063-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic correlates of glandular abnormalities in cervical cytology among women with human immunodeficiency virus.
  • OBJECTIVE: To estimate the frequency and histologic correlates of glandular abnormalities in cervical cytology among women with the human immunodeficiency virus (HIV) and to compare findings with those of women without HIV.
  • Glandular abnormalities, including atypical glandular cells (AGC), adenocarcinoma in situ (AIS), and adenocarcinoma, were identified and correlated with biopsy histology.
  • After index abnormal tests, endocervical curettings were obtained from 106 (43%) women, cervical biopsies from 76 (38%), and endometrial biopsies from 19 (8%).

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Int J STD AIDS. 2006 Dec;17(12):831-4 [17212861.001]
  • [Cites] Obstet Gynecol. 2006 Mar;107(3):701-8 [16507944.001]
  • [Cites] J Low Genit Tract Dis. 2007 Oct;11(4):201-22 [17917566.001]
  • [Cites] Obstet Gynecol. 2008 Jun;111(6):1388-93 [18515523.001]
  • [Cites] Am J Obstet Gynecol. 2007 Dec;197(6):566-71 [18060938.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Cancer. 2009 Feb 1;115(3):524-30 [19127538.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 20;97(8):577-86 [15840880.001]
  • [Cites] Clin Diagn Lab Immunol. 2005 Sep;12(9):1013-9 [16148165.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Nov 1;22(3):247-52 [10770344.001]
  • [Cites] AIDS. 2000 Aug 18;14(12):1775-84 [10985315.001]
  • [Cites] Sex Transm Infect. 2000 Aug;76(4):257-61 [11026879.001]
  • [Cites] Biometrics. 1988 Dec;44(4):1049-60 [3233245.001]
  • [Cites] JAMA. 1994 Jun 15;271(23):1866-9 [8196145.001]
  • [Cites] Epidemiology. 1998 Mar;9(2):117-25 [9504278.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 3;91(3):226-36 [10037100.001]
  • [Cites] Int J Cancer. 1999 Jul 30;82(3):334-7 [10399949.001]
  • (PMID = 20168108.001).
  • [ISSN] 1873-233X
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / UO1-HD-32632; United States / NIAID NIH HHS / AI / UO1-AI-34994; United States / NIAID NIH HHS / AI / UO1-AI-34989; United States / NIAID NIH HHS / AI / U01 AI031834; United States / NIAID NIH HHS / AI / U01 AI035004; United States / NCRR NIH HHS / RR / UL1 RR024131; United States / NIAID NIH HHS / AI / U01 AI034989; United States / NIAID NIH HHS / AI / UO1-AI-35004; United States / NIAID NIH HHS / AI / UO1-AI-34993; United States / NIAID NIH HHS / AI / U01 AI034994; United States / NIAID NIH HHS / AI / U01 AI035004-08S1; United States / NCI NIH HHS / CA / R01-CA-085178; United States / NIAID NIH HHS / AI / AI035004-08S1; United States / NIAID NIH HHS / AI / UO1-AI-42590; United States / NCI NIH HHS / CA / R01 CA085178; United States / NIAID NIH HHS / AI / U01 AI034993; United States / NIAID NIH HHS / AI / UO1-AI-31834; United States / NICHD NIH HHS / HD / U01 HD032632; United States / NIAID NIH HHS / AI / U01 AI042590
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS257741; NLM/ PMC3032588
  •  go-up   go-down


3. Chew GK, Cruickshank ME, Rooney PH, Miller ID, Parkin DE, Murray GI: Human papillomavirus 16 infection in adenocarcinoma of the cervix. Br J Cancer; 2005 Nov 28;93(11):1301-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus 16 infection in adenocarcinoma of the cervix.
  • The impact of the success of organised cervical screening programme results in a steady decline of the incidence of squamous cell carcinoma of the cervix but a concomitant increase in the incidence of the less common histological subtypes, particularly adenocarcinoma of the cervix (ACC).
  • Although Human papillomavirus (HPV) infection is believed to be a necessary cause of cervical cancer, its role in the pathogenesis of ACC is not well established.
  • In this study, the cervical adenocarcinoma cells of a 10-year cohort of women diagnosed with ACC were dissected using the PixCell II Laser Microdissecting System to detect the HPV 16 genome sequence using the real-time quantitative polymerase chain reaction to confirm the presence of HPV DNA within ACC cells.
  • [MeSH-major] Adenocarcinoma / virology. Human papillomavirus 16 / genetics. Human papillomavirus 16 / pathogenicity. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gen Virol. 1999 Jul;80 ( Pt 7):1725-33 [10423141.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Methods Mol Biol. 2005;293:27-37 [16028408.001]
  • [Cites] Lancet. 2000 Jun 24;355(9222):2194-8 [10881892.001]
  • [Cites] Mol Pathol. 2000 Apr;53(2):64-8 [10889904.001]
  • [Cites] Mod Pathol. 1998 Jan;11(1):11-8 [9556417.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2001 Oct;15(5):663-76 [11563866.001]
  • [Cites] Obstet Gynecol. 1980 Sep;56(3):361-4 [7422175.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 18;84(6):394-8 [1311392.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 7;87(11):796-802 [7791229.001]
  • [Cites] Lancet. 2001 May 12;357(9267):1490-3 [11377601.001]
  • (PMID = 16265348.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2361519
  •  go-up   go-down


Advertisement
4. Tawfik El-Mansi M, Cuschieri KS, Morris RG, Williams AR: Prevalence of human papillomavirus types 16 and 18 in cervical adenocarcinoma and its precursors in Scottish patients. Int J Gynecol Cancer; 2006 May-Jun;16(3):1025-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of human papillomavirus types 16 and 18 in cervical adenocarcinoma and its precursors in Scottish patients.
  • Our aim was to determine the prevalence of human papillomavirus (HPV) types 16 and 18 in cervical adenocarcinoma (and its precursors) in Scottish patients.
  • We examined 119 cases of invasive adenocarcinoma, 20 cases of adenocarcinoma in situ, and 16 cases of normal glandular epithelium.
  • Our findings support that HPV-16, along with HPV-18, are likely to play a significant role in the pathogenesis of cervical adenocarcinomas and that cervical cancer screening strategies that incorporate oncogenic HPV testing, and prophylactic vaccines that target these types, will be beneficial for the reduction of adenocarcinoma and associated glandular precursors.
  • [MeSH-major] Adenocarcinoma / virology. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Precancerous Conditions / virology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Carcinoma in Situ / diagnosis. Carcinoma in Situ / virology. Cervical Intraepithelial Neoplasia / epidemiology. Cervical Intraepithelial Neoplasia / etiology. Cervical Intraepithelial Neoplasia / virology. DNA Probes, HPV. Female. Genotype. Humans. Neoplasms, Glandular and Epithelial / epidemiology. Neoplasms, Glandular and Epithelial / etiology. Neoplasms, Glandular and Epithelial / virology. Polymerase Chain Reaction / methods. Polymorphism, Restriction Fragment Length. Prevalence. Scotland / epidemiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803480.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes, HPV
  •  go-up   go-down


5. Ceballos KM, Shaw D, Daya D: Microinvasive cervical adenocarcinoma (FIGO stage 1A tumors): results of surgical staging and outcome analysis. Am J Surg Pathol; 2006 Mar;30(3):370-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microinvasive cervical adenocarcinoma (FIGO stage 1A tumors): results of surgical staging and outcome analysis.
  • Although studies suggest that microinvasive cervical adenocarcinoma has an excellent prognosis, none has reported treatment-related complications and many have lacked detailed measurement criteria.
  • Our study looks at the rate of lymph node metastases and outcome, including complications, in patients with FIGO 1A1 and 1A2 adenocarcinomas of the cervix.
  • One patient died of metastatic ovarian carcinoma 82 months after her diagnosis of cervical carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Neoplasm Staging. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery


6. Mhawech-Fauceglia P, Herrmann F, Bshara W, Zhang S, Penetrante R, Lele S, Odunsi K, Rodabaugh K: Intraobserver and interobserver variability in distinguishing between endocervical and endometrial adenocarcinoma on problematic cases of cervical curettings. Int J Gynecol Pathol; 2008 Jul;27(3):431-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraobserver and interobserver variability in distinguishing between endocervical and endometrial adenocarcinoma on problematic cases of cervical curettings.
  • We conducted a prospective study where 4 pathologists examined patients' problematic cases of cervical curetting for adenocarcinoma to determine whether it is of endocervical or endometrial origin based on 3 parameters: age, morphology, and immunohistochemistry (IHC) panel.
  • The agreements between the diagnosis based on morphology, morphology+age, and the combined parameters compared with the final diagnosis on the hysterectomy specimen were slight (kappa=0.137), fair (kappa=0.290), and moderate (kappa=0.497), respectively.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Endometrial Neoplasms / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580323.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Aximu D, Azad A, Ni R, Colgan T, Nanji S: A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics. Int J Gynecol Pathol; 2009 Mar;28(2):114-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics.
  • The histopathologic distinction of cervical adenocarcinoma in situ (AIS) and invasive adenocarcinoma (AC) from some benign endocervical lesions can be challenging.
  • ProEx C immunohistochemical staining was performed on sections from formalin-fixed, paraffin-embedded tissue of 65 cervical tissues including 48 non-neoplastic cervices (normal [n=10], microglandular hyperplasia [n=10], tubal metaplasia [n=11], cervical endometriosis [n=7], reactive endocervix [n=10]) and 17 cervices with glandular malignancy (AIS [n=12] and AC [n=5]).
  • The median and distribution of scores for both prevalence and intensity was compared for AIS versus each of the 5 benign cervical lesions using a Mann-Whitney U test.
  • ProEx C reagent has potential as an adjunctive testing tool in the histopathologic diagnosis of both AIS and AC, particularly in difficult cases with small biopsies or foci of disease.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, Neoplasm / biosynthesis. Cell Cycle Proteins / biosynthesis. Cervical Intraepithelial Neoplasia / diagnosis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Immunohistochemistry / methods. Nuclear Proteins / biosynthesis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Minichromosome Maintenance Complex Component 2. Pilot Projects. Reagent Kits, Diagnostic

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188825.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Reagent Kits, Diagnostic; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


8. Ogura K, Ishi K, Matsumoto T, Kina K, Nojima M, Suda K: Human papillomavirus localization in cervical adenocarcinoma and adenosquamous carcinoma using in situ polymerase chain reaction: review of the literature of human papillomavirus detection in these carcinomas. Pathol Int; 2006 Jun;56(6):301-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus localization in cervical adenocarcinoma and adenosquamous carcinoma using in situ polymerase chain reaction: review of the literature of human papillomavirus detection in these carcinomas.
  • Many studies have suggested that human papillomavirus (HPV) infection plays an important role in the carcinogenesis of the cervical adenocarcinoma.
  • However, the prevalence of HPV infection in cervical adenocarcinoma and adenosquamous carcinoma varies among the studies.
  • Cervical adenocarcinoma (24 cases) and adenosquamous carcinoma (16 cases), including the underlying non-neoplastic epithelium were examined for HPV-DNA using in situ polymerase chain reaction (PCR), which enabled visualization of the localization on a glass slide.
  • In adenocarcinoma, HPV-DNA was found in 13 cases (54%) and in eight cases in underlying non-neoplastic epithelium, resulting in a total of 21 positive cases (88%).
  • In adenosquamous carcinoma, HPV-DNA was detected in 12 cases (75%) and and the HPV-DNA localization of each component was pure adenocarcinoma, 28.6%; mixed, 54.5%; and pure squamous cell carcinoma, 83.3%.
  • In the underlying non-neoplastic epithelium, HPV-DNA was found more frequently in the squamous epithelium (73.3%) than the cervical glands (6.3%).
  • In conclusion, HPV-DNA was detected in 54% of adenocarcinoma, and the rate was elevated by HPV localization in the underlying non-neoplastic epithelium.
  • HPV infection in the underlying squamous epithelium might be related to the carcinogenesis, even in cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Adenosquamous / virology. Papillomaviridae / isolation & purification. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / virology


9. Hashi A, Yuminamochi T, Xu JY, Kondo T, Katoh R, Hoshi K: Intranuclear cytoplasmic inclusion is a significant diagnostic feature for the differentiation of lobular endocervical glandular hyperplasia from minimal deviation adenocarcinoma of the cervix. Diagn Cytopathol; 2008 Aug;36(8):535-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intranuclear cytoplasmic inclusion is a significant diagnostic feature for the differentiation of lobular endocervical glandular hyperplasia from minimal deviation adenocarcinoma of the cervix.
  • Lobular endocervical glandular hyperplasia (LEGH) is a cervical lesion with pyloric gland metaplasia.
  • Minimal deviation adenocarcinoma (MDA) is an extremely well differentiated form of endocervical adenocarcinoma (AC).
  • We reviewed 24 cases of LEGH (18 pure and six mixed forms) and four MDA cases of the cervix.
  • Abundant yellow mucin was frequently present in both LEGH and MDA; however, an INCI was found in 22 of the 24 LEGH cases and it was not found in either MDA or adenocarcinoma cells associated with LEGH.
  • The presence of an INCI is a good parameter for the diagnosis of LEGH.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Cytoplasm / pathology. Intranuclear Inclusion Bodies / pathology. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Cervix Uteri. Diagnosis, Differential. Female. Humans. Hyperplasia. Middle Aged


10. Hamer OW, Flint J, Ryan CF, Manos D, Müller NL: Mucoid impaction secondary to mucin-producing metastatic adenocarcinoma of the cervix. Br J Radiol; 2008 Aug;81(968):e201-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoid impaction secondary to mucin-producing metastatic adenocarcinoma of the cervix.
  • Here, we describe an uncommon case of endobronchial metastasis of adenocarcinoma of the cervix causing mucoid impaction owing to mucous production by the tumour cells.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Bronchial Neoplasms / secondary. Uterine Cervical Neoplasms


11. Nagai N, Hirata E, Kusuda T, Mukai K, Arihiro K, Ohama K: Villoglandular papillary adenocarcinoma of the uterine cervix responding to neoadjuvant chemotherapy with docetaxel and cisplatin: a case report. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1187-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of the uterine cervix responding to neoadjuvant chemotherapy with docetaxel and cisplatin: a case report.
  • Villoglandular papillary adenocarcinoma (VGPA) of the uterine cervix is a rare neoplasm, and its treatment has rarely been reported.
  • Thus, the combination of docetaxel and cisplatin is suggested to be useful for neoadjuvant chemotherapy of cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Adenocarcinoma, Papillary / pathology. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343210.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Csapi B, Hajdú Z, Zupkó I, Berényi A, Forgo P, Szabó P, Hohmann J: Bioactivity-guided isolation of antiproliferative compounds from Centaurea arenaria. Phytother Res; 2010 Nov;24(11):1664-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The antiproliferative effects of n-hexane, chloroform and aqueous methanol extracts prepared from the whole plant of Centaurea arenaria M.B. ex Willd. were investigated against cervix adenocarcinoma (HeLa), breast adenocarcinoma (MCF7) and skin epidermoid carcinoma (A431) cells, using the MTT assay.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • (PMID = 21031625.001).
  • [ISSN] 1099-1573
  • [Journal-full-title] Phytotherapy research : PTR
  • [ISO-abbreviation] Phytother Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Flavonoids; 0 / Plant Extracts; 0 / Sesquiterpenes
  •  go-up   go-down


13. Robova H, Pluta M, Hrehorcak M, Skapa P, Rob L: High-dose density chemotherapy followed by simple trachelectomy: full-term pregnancy. Int J Gynecol Cancer; 2008 Nov-Dec;18(6):1367-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report five patients with early-stage cervical cancer who do not fulfill criteria of fertility-sparing surgery (tumor more than 2 cm in the biggest diameter or infiltrating more than half of stroma).
  • Five patients received three cycles of dose density neoadjuvant chemotherapy (NAC) at a 10-day interval: cisplatin plus ifosfamide in squamous cell cancer or plus doxorubicin in adenocarcinoma with good tolerance.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cervix Uteri / surgery. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / surgery


14. Song SH, Lee JK, Saw HS, Choi SY, Koo BH, Kim A, Yeom BW, Kim I: Peutz-Jeghers Syndrome with multiple genital tract tumors and breast cancer: a case report with a review of literatures. J Korean Med Sci; 2006 Aug;21(4):752-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peutz-Jeghers Syndrome with multiple genital tract tumors and breast cancer: a case report with a review of literatures.
  • Her previous medical history was PJS and breast cancer.
  • An ovarian sex cord tumor with annular tubules was incidentally diagnosed together with a minimal deviation adenocarcinoma of the uterine cervix and mucinous metaplasia of both the Fallopian tubal mucosa and the endometrium.
  • The clinical significance of the multiple genital tract tumors and breast cancer associated with PJS is reviewed.
  • [MeSH-major] Breast Neoplasms / pathology. Ovarian Neoplasms / pathology. Peutz-Jeghers Syndrome / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / pathology. Adult. Carcinoma, Ductal, Breast / complications. Carcinoma, Ductal, Breast / pathology. Endometrium / pathology. Fallopian Tubes / pathology. Female. Humans. Korea. Metaplasia. Sex Cord-Gonadal Stromal Tumors / complications. Sex Cord-Gonadal Stromal Tumors / pathology


15. Srilatha PS, Roy A: Villoglandular papillary adenocarcinoma of cervix associated with cervical intraepithelial neoplasia: a case report and review of literature. Indian J Pathol Microbiol; 2007 Oct;50(4):819-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of cervix associated with cervical intraepithelial neoplasia: a case report and review of literature.
  • Well differentiated villoglandular adenocarcinoma of uterine cervix is a rare tumour which usually occurs in young women.
  • Physical examination revealed a cervical polyp.
  • Histopathological findings were consistent with villoglandular papillary adenocarcinoma associated with high grade cervical intraepithelial neoplasia (CIN-3).
  • [MeSH-major] Adenocarcinoma, Papillary / complications. Adenocarcinoma, Papillary / pathology. Cervical Intraepithelial Neoplasia / complications. Cervical Intraepithelial Neoplasia / pathology. Uterine Cervical Neoplasms / complications. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adnexa Uteri / pathology. Adult. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Female. Humans. Hydronephrosis. Polyps. Ureter / pathology


16. Li F, Awale S, Tezuka Y, Kadota S: Cytotoxic constituents of propolis from Myanmar and their structure-activity relationship. Biol Pharm Bull; 2009 Dec;32(12):2075-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirteen cycloartane-type tritepenes (1-13) and four prenylated flavanones (14-17) isolated from propolis collected in Myanmar, were evaluated for their cytotoxic activity against a panel of six different cancer cell lines; three murine cancer cell lines (colon 26-L5 carcinoma, B16-BL6 melanoma, and Lewis lung carcinoma) and three human cancer cell lines (lung A549 adenocarcinoma, cervix HeLa adenocarcinoma and HT-1080 fibrosarcoma).
  • In addition, (2S)-5,7-dihydroxy-4'-methoxy-8,3'-diprenylflavanone (14) exhibited strong cytotoxicity against all the tested cancer cell lines with the IC(50) values ranging from 14.0 to 26.4 microM.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • National BioResource Project. culture/stock collections - NBRP resources .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952433.001).
  • [ISSN] 1347-5215
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Flavanones; 0 / Triterpenes; 511-64-8 / cycloartane; 9009-62-5 / Propolis
  •  go-up   go-down


17. Nola M, Tomicic I, Dotlic S, Morovic A, Petrovecki M, Jukic S: Adenocarcinoma of uterine cervix -- prognostic significance of clinicopathologic parameters. Croat Med J; 2005 Jun;46(3):397-403
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of uterine cervix -- prognostic significance of clinicopathologic parameters.
  • AIM: To investigate prognostic significance of several clinicopathologic parameters in patients with adenocarcinoma of the uterine cervix.
  • CONCLUSION: Our data showed that in patients with adenocarcinoma of the uterine cervix the nuclear grade, clinical stage, and architectural grade of the tumor represent the most important prognostic parameters.
  • [MeSH-major] Adenocarcinoma / mortality. Uterine Cervical Neoplasms / mortality


18. McCluggage WG, Young RH: Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol; 2005 Feb;22(1):3-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aspects of immunohistochemistry (IHC), which are useful in the diagnosis of ovarian tumors (mostly neoplasms but also a few tumor-like lesions), are discussed.
  • IHC for neuroendocrine markers may assist in the diagnosis of primary and metastatic carcinoid tumor.
  • The broad differential diagnosis of glandular neoplasms with an endometrioid-pseudoendometrioid morphology, or mucinous cell type, has been the subject of much exploration in recent years, particularly the distinction between primary and metastatic neoplasms.
  • The well-known CK7 positive, CK20 negative phenotype of primary endometrioid carcinoma, and the converse profile in most metastatic large intestinal adenocarcinomas with a pseudoendometrioid morphology, has been much publicized but albeit an appropriate supportive adjunct in many cases, exceptions from the typical staining pattern may be encountered.
  • The rare differential of metastatic cervical adenocarcinoma versus primary ovarian mucinous or endometrioid carcinoma may be aided by strong p16 staining of the former.
  • Staining for alpha-fetoprotein may aid in confirming the diagnosis of endometrioid-like (and hepatoid) variants of yolk sac tumor.
  • As in tumor pathology in general, various markers may be crucial in the diagnosis of small round cell tumors of the ovary, and familiar markers of epithelial, lymphoid, leukemic, and melanocytic neoplasms may assist in the analysis of high grade tumors with a poorly differentiated carcinoma, lymphoma-granulocytic sarcoma, malignant melanoma differential.
  • [MeSH-major] Immunohistochemistry. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis. Ovarian Cysts / diagnosis. Ovarian Follicle / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512597.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 115
  •  go-up   go-down


19. Behtash N, Nazari Z, Fakhrejahani F, Khafaf A, Azar EG: Clinical and histological significance of atypical glandular cell on Pap smear. Aust N Z J Obstet Gynaecol; 2007 Feb;47(1):46-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty-one women underwent colposcopy-directed biopsy, endocervical curettage, endometrial sampling and cervical conisation to determine the cytological and histological correlations of AGC on Pap smears.
  • We found eight (19.5%) significant pathological findings including four (9.7%) high-grade squamous intraepithelial lesion, one (2.4%) adenocarcinoma of uterus, one (2.4%) adenocarcinoma of cervix, one (2.4%) squamous cell carcinoma of cervix and one (2.4%) papillary serous tumour of ovary.
  • CONCLUSION: AGC on Pap smear was associated with a clinically significant diagnosis in approximately 20% of our cases.
  • The women with a diagnosis of AGC on cervicovaginal smear are needed to be evaluated at least with colposcopy, endocervical and endometrial curettage.
  • [MeSH-major] Papanicolaou Test. Uterine Cervical Neoplasms / pathology. Vaginal Smears
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Cervix Uteri / pathology. Colposcopy. Conization. Dilatation and Curettage. Endometrium / pathology. Female. Humans. Iran. Middle Aged. Prospective Studies


20. Wang Z, Zhang T, Hu H, Zhang H, Yang Z, Cui L, He W: Targeting solid tumors via T cell receptor complementarity-determining region 3delta in an engineered antibody. Cancer Lett; 2008 Dec 18;272(2):242-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, immunotoxin OT3-DT, CDR3delta-grafted antibody OT3 chemically conjugated with diphtheria toxin (DT) showed the anti-tumor effect on the growth of several solid tumors including OEC, cervix adenocarcinoma, hepatocellular carcinoma, and rectum adenocarcinoma to various extents in nude mice.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18782650.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Complementarity Determining Regions; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


21. Baek KH, Lee HJ, Kim MS, Kim YS, Seong M, Lee EJ, Lee MY: Molecular cloning of rHAUSP encoding a deubiquitinating enzyme in rat testis. Oncol Rep; 2006 Jan;15(1):173-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The over-expression of rHAUSP induced cell death of cervical adenocarcinoma cells.


22. Boyadzhieva M, Atanassova I, Dimitrova V, Zaharieva S, Tankova T, Grozeva G, Todorova K, Stoykova V, Kedikova S: [Our and foreign experience in surgical treatment of CIN III-cold knife conisation versus LLETZ]. Akush Ginekol (Sofiia); 2010;49(3):9-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Invasive disease and recurrence were observed in 150 patients--50 of them having adenocarcinoma in situ.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / surgery. Conization / methods. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Cervix Uteri / pathology. Cervix Uteri / surgery. Female. Humans. Laser Therapy / instrumentation. Laser Therapy / methods. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery


23. Ko ML, Jeng CJ, Huang SH, Shen J, Chen SC, Tzeng CR: Large cell neuroendocrine carcinoma of the uterine cervix associated with adenocarcinoma. Taiwan J Obstet Gynecol; 2007 Mar;46(1):68-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell neuroendocrine carcinoma of the uterine cervix associated with adenocarcinoma.
  • OBJECTIVE: Large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive cervical neoplasm.
  • In the present study, we present a 45-year-old woman with large cell neuroendocrine uterine cervical carcinoma with coexisting adenocarcinoma.
  • On pelvic examination, a polypoid mass of the cervix was discovered.
  • Biopsy of the lesion revealed large cell neuroendocrine carcinoma of the cervix.
  • CONCLUSION: Patients with LCNEC of the cervix have had poor prognoses; hence aggressive multimodality treatment is recommended.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Neoplasms, Multiple Primary / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Cervix Uteri / pathology. Female. Humans. Middle Aged. Treatment Outcome


24. Niwa T, Yoshida T, Doiuchi T, Ito K, Nakayama H, Odagiri K, Inoue T: Factors predicting tumour regression in locally advanced cervical adenocarcinoma treated with balloon-occluded intra-arterial chemotherapy. Br J Radiol; 2008 Aug;81(968):659-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors predicting tumour regression in locally advanced cervical adenocarcinoma treated with balloon-occluded intra-arterial chemotherapy.
  • We retrospectively assessed the factors that may impede tumour reduction of locally advanced cervical adenocarcinoma treated with balloon-occluded arterial infusion chemotherapy (BOAI) as initial therapy.
  • BOAI was performed via uterine arteries in 21 patients, and via the anterior division or main trunk of the internal iliac artery (when the uterine arteries were obscured) in 10 patients.
  • Internal iliac arterial infusion significantly correlated with "no response" compared with uterine arterial infusion (p<0.001).
  • These data suggest that uterine arteries being obscured to arterial infusion may be associated with a poor response to BOAI for cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628334.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. McCluggage WG, Shah R, Connolly LE, McBride HA: Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2. Int J Gynecol Pathol; 2008 Jan;27(1):92-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
  • Most cases of cervical adenocarcinoma in situ (AIS) and adenocarcinoma are of the usual or endocervical type.
  • However, intestinal types of AIS and adenocarcinoma exist.
  • With an intestinal-type adenocarcinoma in the cervix, the question may arise as to whether one is dealing with a primary cervical neoplasm or direct or secondary spread from an intestinal adenocarcinoma.
  • In organs such as the ovary, urinary bladder, esophagus, and gallbladder, intestinal-type glandular epithelium often expresses enteric markers, but this has hardly been studied in the cervix.
  • The purpose of this study was to investigate whether intestinal-type AIS and adenocarcinoma in the cervix express enteric markers and to ascertain whether these antibodies are of value in the distinction from a metastatic intestinal adenocarcinoma.
  • We compared the immunophenotype of these lesions with that of usual-type AIS and adenocarcinomain the cervix.
  • Cases included were AIS of usual type (n = 6), primary cervical adenocarcinoma of usual type (n = 6), AIS of intestinal type (n = 21), primary cervical adenocarcinoma of intestinal type (n = 3), primary cervical adenocarcinoma with signet ring cells (n = 2), and colorectal adenocarcinoma involving the cervix (n = 5).
  • All usual cervical adenocarcinomas were diffusely CK7 and p16 positive, and all were immunoreactive with CEA.
  • The 3 cases of primary cervical intestinal-type adenocarcinoma were diffusely CK7 positive, focally or diffusely positive with CK20 and CDX2, and focally positive with CEA.
  • The foci of signet ring cells in the 2 primary cervical adenocarcinomas were diffusely CK7 and p16 positive and negative with CK20 and CDX2.
  • Colorectal adenocarcinomas involving the cervix were typically diffusely positive with CK20, CEA, and CDX2; negative with CK7; and negative or focally positive with p16.
  • Intestinal types of cervical AIS and adenocarcinoma exhibit a partial enteric immunophenotype, usually with diffuse expression of CDX2 and, in some cases, staining with CK20.
  • Although there is immunophenotypic overlap, focal staining with CK20 together with diffuse CK7 and sometimes p16 positivity helps to distinguish intestinal types of cervical adenocarcinoma from involvement by a colorectal adenocarcinoma; CEA and CDX2 are of no value in this regard.
  • Using a set of cases of AIS diagnosed in a single institution over a 7-year period (77 usual type; 13 intestinal type), intestinal type was more likely to be associated with early invasive adenocarcinoma than usual type (31% vs 17%), suggesting that intestinal differentiation may be a risk factor for invasion in premalignant cervical glandular lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Homeodomain Proteins / biosynthesis. Intestinal Neoplasms / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoembryonic Antigen / biosynthesis. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Immunophenotyping. Keratin-20 / biosynthesis. Keratin-7 / biosynthesis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156982.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Carcinoembryonic Antigen; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


26. Ergünay K, Misirlioğlu M, Firat P, Tuncer ZS, Tuncer S, Yildiz I, Ustaçelebi S: [Detection and typing of human papilloma virus by polymerase chain reaction and hybridization assay in cervical samples with cytological abnormalities]. Mikrobiyol Bul; 2008 Apr;42(2):273-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection and typing of human papilloma virus by polymerase chain reaction and hybridization assay in cervical samples with cytological abnormalities].
  • Certain mucosa-tropic human papillomavirus (HPV) types are associated with carcinoma of the uterine cervix or its precursor lesions.
  • In addition to cytological screening, early diagnosis and treatment of cervical carcinoma rely on sensitive detection and typing of HPV isolates.
  • In this study, HPV detection and typing were performed in the cervical samples of patients with abnormal cytological evaluation.
  • Forty randomly-selected cervical samples that comprise 18 ASC-US (Aypical Squamous Cells of Undetermined Significance), four AG-US (Aypical Glandular cells of Undetermined Significance), one ASC-H (Atypical Squamous Cells-can not exclude HSIL), one HSIL (High-grade Intraepithelial Lesion), 14 LSIL (Low-grade Intraepithelial Lesion), one adenocarcinoma and one squamous cell carcinoma, obtained by a commercial liquid-based cytology system (ThinPrep Pap Smear Method, Cytyc, USA), were included to the study.
  • [MeSH-major] Cervix Uteri / virology. Papillomaviridae / classification. Papillomaviridae / isolation & purification. Uterine Cervical Dysplasia / virology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adenocarcinoma / virology. Carcinoma, Squamous Cell / virology. DNA, Viral / analysis. Female. Humans. Nucleic Acid Hybridization. Polymerase Chain Reaction / methods


27. Lin Z, Gao M, Zhang X, Kim YS, Lee ES, Kim HK, Kim I: The hypermethylation and protein expression of p16 INK4A and DNA repair gene O6-methylguanine-DNA methyltransferase in various uterine cervical lesions. J Cancer Res Clin Oncol; 2005 Jun;131(6):364-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The hypermethylation and protein expression of p16 INK4A and DNA repair gene O6-methylguanine-DNA methyltransferase in various uterine cervical lesions.
  • PURPOSE: This study is aimed at investigating the significance of gene promoter methylation status and protein expression of p16 INK4A and O6-methylguanine-DNA methyltransferase (MGMT) in the various uterine cervical lesions.
  • MATERIALS AND METHODS: Methylation status by using methylation-specific polymerase chain reaction (MS-PCR) and protein expression by using immunohistochemistry for p16 INK4A and MGMT genes were performed in cervical squamous intraepithelial neoplasms (CIN), invasive squamous cell carcinomas (SCC), adenocarcinomas and non-neoplastic cervices.
  • RESULTS: None of 20 non-neoplastic cervices showed p16 INK4A and MGMT gene hypermethylation, whereas at least one of these genes was hypermethylated with 50.0% (5/10) of CIN I, 65.0% (13/20) of CIN II-III, 70.2% (33/47) of SCC and 85.0% (17/20) of adenocarcinoma. p16 INK4A protein was totally negative in non-neoplastic cervices, but positive with 90.0% of CIN I, 100% of CIN II-III and adenocarcinoma, and 78.7% of SCC.
  • MGMT protein was expressed in 10% of non-neoplastic cervices, but significantly increased in SCC (42.5%) and adenocarcinoma (70.0%).
  • CONCLUSIONS: The hypermethylation of p16 INK4A and MGMT genes in the uterine cervix may indicate the presence of malignant cells, and p16 INK4A immunostaining is useful in grading CIN and diagnosing invasive SCC and adenocarcinoma.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Methylation. O(6)-Methylguanine-DNA Methyltransferase / genetics. Promoter Regions, Genetic. Uterine Cervical Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / genetics. Cervical Intraepithelial Neoplasia / metabolism. Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / metabolism. DNA / metabolism. DNA Repair. Female. Gene Silencing. Humans. Immunoenzyme Techniques. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / pathology. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1517-23 [14562026.001]
  • [Cites] Lancet Oncol. 2002 Jan;3(1):11-6 [11905599.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6289-93 [7603984.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 May;43(5):1344-9 [11980845.001]
  • [Cites] Ann Surg Oncol. 2002 May;9(4):371-9 [11986189.001]
  • [Cites] Neurol Res. 2003 Apr;25(3):241-8 [12739231.001]
  • [Cites] Gynecol Oncol. 1997 May;65(2):319-24 [9159345.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):939-42 [11221887.001]
  • [Cites] Diagn Mol Pathol. 1998 Dec;7(6):324-30 [10207671.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):435-40 [15099958.001]
  • [Cites] Mol Carcinog. 1999 Feb;24(2):90-8 [10078936.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11891-6 [9751761.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4531-5 [7553622.001]
  • [Cites] J Natl Cancer Inst. 1998 Mar 18;90(6):433-9 [9521167.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5360-8 [9393761.001]
  • [Cites] J Biol Chem. 1983 Feb 25;258(4):2327-33 [6822564.001]
  • [Cites] J Natl Cancer Inst. 2000 May 17;92(10):826-32 [10814678.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):200-7 [15279712.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2981-4 [12912945.001]
  • [Cites] J Natl Cancer Inst. 2002 Sep 18;94(18):1406-14 [12237286.001]
  • [Cites] Am J Obstet Gynecol. 2004 Mar;190(3):674-9 [15041998.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):276-84 [11291057.001]
  • [Cites] Cell. 1981 Apr;24(1):33-40 [6263490.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1982-6 [11448914.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):584-9 [11297252.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(6):547-55 [8612308.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):187-93 [12548164.001]
  • [Cites] Genes Dev. 1999 Jan 1;13(1):26-34 [9887097.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):69-72 [9662253.001]
  • [Cites] Pathol Int. 2002 May-Jun;52(5-6):375-83 [12100520.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3416-20 [8324751.001]
  • [Cites] Nat Med. 1995 Jul;1(7):686-92 [7585152.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):689-96 [15188135.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 4;84(5):337-40 [1738185.001]
  • [Cites] Oncology. 1999;56(1):83-7 [9885382.001]
  • [Cites] Virchows Arch. 2001 Jul;439(1):55-61 [11499840.001]
  • [Cites] Cell. 1988 Apr 8;53(1):3-4 [3280142.001]
  • [Cites] Trends Cell Biol. 1994 Jan;4(1):15-8 [14731824.001]
  • [Cites] Gynecol Oncol. 2001 Aug;82(2):299-304 [11531283.001]
  • [Cites] Clin Cancer Res. 1996 Mar;2(3):577-84 [9816206.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):1004-14; discussion 1014 [14675710.001]
  • [Cites] Carcinogenesis. 1998 Jul;19(7):1247-50 [9683184.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):807-10 [10029067.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):591-3 [9485004.001]
  • [Cites] Cancer Res. 1991 Aug 15;51(16):4131-4 [1868433.001]
  • (PMID = 15785933.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 9007-49-2 / DNA; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


28. Yemelyanova A, Vang R, Seidman JD, Gravitt PE, Ronnett BM: Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor. Am J Surg Pathol; 2009 Jun;33(6):914-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor.
  • Determining the primary site of a uterine adenocarcinoma can be problematic in hysterectomy specimens due to the overlapping morphology of endocervical adenocarcinomas and endometrial carcinomas, particularly when both the corpus (usually lower uterine segment) and endocervix are involved and precursor lesions are lacking or difficult to distinguish from intramucosal spread of carcinoma from one site to the other.
  • Both preferential extension of endocervical adenocarcinomas into the endometrium (rather than deep cervical stroma) and myometrial invasion derived from the endometrial component are rarely encountered; to our knowledge, these unusual patterns of spread have not been detailed in prior reports.
  • Clinicopathologic features of 10 endocervical adenocarcinomas (9 pure, 1 adenosquamous) with prominent endometrial or endomyometrial involvement were evaluated.
  • Six cases had limited amounts of tumor in the cervix proper, with depths of invasion no greater than 5 mm in 4 and only adenocarcinoma in situ in 2.
  • Four cases had cervical stromal invasion of more than 5 mm but all of these had greater amounts of horizontal extension into endometrium or endomyometrium.
  • Five tumors were originally diagnosed as primary endometrial carcinoma with either cervical extension or concurrent endocervical adenocarcinoma in situ.
  • HPV DNA was detected in both the cervical and corpus components in all tumors and all exhibited diffuse/strong p16 expression and decreased or absent expression of hormone receptors.
  • These ancillary techniques are useful for clarifying the origin of uterine adenocarcinomas when morphologic features and tumor location are equivocal.
  • These cases illustrate that dominant uterine corpus involvement (endometrial or endomyometrial) by primary endocervical adenocarcinoma can lead to misclassification as primary endometrial adenocarcinoma with cervical extension (Fédération Internationale de Gynécologie et d'Obstétrique stage II), especially when endometrial extension of endocervical adenocarcinoma simulates complex atypical hyperplasia.
  • A subset of misclassified endocervical adenocarcinomas may account for some HPV-positive uterine carcinomas reported as primary endometrial carcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. DNA, Viral / analysis. Endometrial Neoplasms / diagnosis. Receptors, Steroid / biosynthesis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Endometrium / metabolism. Endometrium / pathology. Endometrium / virology. Female. Humans. Immunohistochemistry. In Situ Hybridization. Middle Aged. Papillomaviridae. Papillomavirus Infections / diagnosis. Papillomavirus Infections / metabolism. Papillomavirus Infections / pathology. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis


29. Feddock J, Kudrimoti M, Randall M: No cookie-cutter oncology: individualized treatment approaches for women with corpus endometrial cancer. Expert Rev Anticancer Ther; 2010 Jul;10(7):1087-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No cookie-cutter oncology: individualized treatment approaches for women with corpus endometrial cancer.
  • Endometrial adenocarcinoma is the most common gynecologic malignancy and, for the majority of patients who present with stage I (approximately 70%) or stage II ( approximately 10%) disease, 5-year overall survival rates approach 85%.
  • [MeSH-major] Adenocarcinoma / therapy. Endometrial Neoplasms / therapy. Precision Medicine
  • [MeSH-minor] Aged. Algorithms. Antineoplastic Agents, Hormonal / therapeutic use. Brachytherapy. Cervix Uteri / pathology. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Comorbidity. Decision Making. Female. Humans. Hysterectomy. Lymph Node Excision. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Risk

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20645698.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


30. Almog B, Gutman G, Lessing JB, Grisaru D: Prediction of cervical involvement in endometrial cancer by hysteroscopy. Arch Gynecol Obstet; 2007 Jan;275(1):45-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of cervical involvement in endometrial cancer by hysteroscopy.
  • OBJECTIVE: This study evaluated the ability of hysteroscopy to preoperatively predict cervical involvement in endometrial cancer.
  • METHODS: The records of 110 surgically staged consecutive endometrial cancer patients treated at our institution from 1997 to 2003 were retrospectively analyzed.
  • RESULTS: Fourteen (12.7%) patients had cervical involvement (stage II) according to the surgical pathology report, of whom nine (8.1%) had stage IIA and five (4.6%) had stage IIB.
  • Clinical evaluation by speculoscopy and palpation had failed to reveal any indication of cervical involvement.
  • None of the hysteroscopy procedures revealed any suspicious lesion in the cervical canal.
  • CONCLUSION: Hysteroscopy and clinical examination fail to adequately predict cervical involvement in endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Hysteroscopy. Neoplasm Staging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cervix Uteri / pathology. Female. Humans. Middle Aged. Predictive Value of Tests. Retrospective Studies

  • Genetic Alliance. consumer health - Cervical cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16906402.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Stanojkovic TP, Zizak Z, Mihailovic-Stanojevic N, Petrovic T, Juranic Z: Inhibition of proliferation on some neoplastic cell lines-act of carvedilol and captopril. J Exp Clin Cancer Res; 2005 Sep;24(3):387-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present work examines the effects of beta and alpha1-adrenoceptor antagonist carvedilol, and angiotensin converting enzyme (ACE) inhibitor captopril, on in vitro growth of tumor cell lines derived from breast tumor (MDA-MB-361), melanoma (Fem-x), cervix adenocarcinoma (HeLa) and human myelogenous leukemia (K562).
  • The order of sensitivity of various human cell lines to carvedilol's antiproliferative action was: myelogenous leukemia K562 (IC50 = 22.66 +/- 2.14 micromol), > cervix carcinoma HeLa (IC50 = 30.56 +/- 5.16 micromol), > melanoma Fem-x (IC50 = 32.17 +/- 5.75 micromol), > breast tumor MDA-MB-361 (IC50 = 35.04 +/- 2.95 micromol).
  • Understanding the action of these established and clinically accepted agents could provide a basis for design of improved therapeutic regimens in the treatment of cancer diseases.

  • Hazardous Substances Data Bank. CAPTOPRIL .
  • Hazardous Substances Data Bank. CARVEDILOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270525.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Carbazoles; 0 / Propanolamines; 0K47UL67F2 / carvedilol; 9G64RSX1XD / Captopril
  •  go-up   go-down


32. Kuo KT, Liang CW, Hsiao CH, Lin CH, Chen CA, Sheu BC, Lin MC: Downregulation of BRG-1 repressed expression of CD44s in cervical neuroendocrine carcinoma and adenocarcinoma. Mod Pathol; 2006 Dec;19(12):1570-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of BRG-1 repressed expression of CD44s in cervical neuroendocrine carcinoma and adenocarcinoma.
  • Neuroendocrine carcinomas of the uterine cervix are rare tumors with early metastases, highly aggressive clinical behavior, and poor clinical outcome.
  • We have examined the expression of the standard CD44 (CD44s) by immunohistochemical stains in the paraffin-embedded cervical neoplasm tissue of 17 cases of primary cervical neuroendocrine carcinoma, 28 cases of cervical adenocarcinoma, and 50 cases of cervical squamous cell carcinoma.
  • Loss of CD44s expression was found in 16 of 17 neuroendocrine carcinomas, 14 of 28 adenocarcinomas, and three of 50 squamous cell carcinomas.
  • Loss of BRG-1 expression was observed in 12/16, 6/14, and 1/3 CD44s-negative neuroendocrine carcinomas, adenocarcinomas, and squamous cell carcinomas, respectively.
  • This study suggests that loss of the CD44s molecule may imply special biological behaviors of cervical neuroendocrine carcinomas, and loss of expression of BRG-1 may contribute to this.
  • [MeSH-major] Antigens, CD44 / metabolism. Carcinoma, Neuroendocrine / metabolism. Carcinoma, Squamous Cell / metabolism. DNA Helicases / metabolism. Down-Regulation. Nuclear Proteins / metabolism. Transcription Factors / metabolism. Uterine Cervical Neoplasms / metabolism


33. Choi JS, Shin S, Jin YH, Yim H, Koo KT, Chun KH, Oh YT, Lee WH, Lee SK: Cyclin-dependent protein kinase 2 activity is required for mitochondrial translocation of Bax and disruption of mitochondrial transmembrane potential during etoposide-induced apoptosis. Apoptosis; 2007 Jul;12(7):1229-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies have suggested that upregulation of Cyclin A-dependent protein kinase 2 (Cdk2) activity is an essential event in apoptotic progression and the mitochondrial permeability transition in human cancer cells.
  • Here, we show that upregulated Cyclin A/Cdk2 activity precedes the proteolytic cleavage of PARP and is correlated with the mitochondrial translocation of Bax and the loss of mitochondrial transmembrane potential (Deltapsim) during etoposide-induced apoptosis in human cervical adenocarcinoma (HeLa) cells.

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252195.001).
  • [ISSN] 1360-8185
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin A; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / bcl-2-Associated X Protein; 6PLQ3CP4P3 / Etoposide; EC 2.4.2.30 / PARP1 protein, human; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2
  •  go-up   go-down


34. Bilton R, Mazure N, Trottier E, Hattab M, Déry MA, Richard DE, Pouysségur J, Brahimi-Horn MC: Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1alpha and is not induced by hypoxia or HIF. J Biol Chem; 2005 Sep 2;280(35):31132-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, we show that the ARD1 mRNA and protein levels are not regulated by hypoxia in several human tumor cell lines, including cervical adenocarcinoma HeLa cells, fibrosarcoma HT1080 cells, adenovirus-transformed human kidney HEK293 cells, and human breast cancer MCF-7 cells.

  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Biol Chem. 2006 Jun 2;281(22):15592
  • (PMID = 15994306.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / HIF1A protein, human; 0 / Hif1a protein, mouse; 0 / Hypoxia-Inducible Factor 1; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / endothelial PAS domain-containing protein 1; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.88 / N-Terminal Acetyltransferase A; EC 2.3.1.88 / N-Terminal Acetyltransferase E; EC 2.3.1.88 / NAA10 protein, human
  •  go-up   go-down


35. Han YH, Moon HJ, You BR, Park WH: The anti-apoptotic effects of caspase inhibitors on propyl gallate-treated HeLa cells in relation to reactive oxygen species and glutathione levels. Arch Toxicol; 2009 Sep;83(9):825-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we evaluated the anti-apoptotic effects of caspase inhibitors on PG-treated human cervix adenocarcinoma HeLa cells in relation to the changes of reactive oxygen species (ROS) and glutathione (GSH) levels.

  • Hazardous Substances Data Bank. PROPYL GALLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19434396.001).
  • [ISSN] 1432-0738
  • [Journal-full-title] Archives of toxicology
  • [ISO-abbreviation] Arch. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / Annexin A5; 0 / Antioxidants; 0 / Caspase Inhibitors; 0 / Enzyme Inhibitors; 0 / Oligopeptides; 0 / Reactive Oxygen Species; 0 / benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone; 0 / benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone; 0 / benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 8D4SNN7V92 / Propyl Gallate; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9; GAN16C9B8O / Glutathione
  •  go-up   go-down


36. Djordjevic B, Clement-Kruzel S, Atkinson NE, Malpica A: Nodal endosalpingiosis in ovarian serous tumors of low malignant potential with lymph node involvement: a case for a precursor lesion. Am J Surg Pathol; 2010 Oct;34(10):1442-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We first examined the frequency of nodal endosalpingiosis in 30 OSLMP cases, 30 cervical adenocarcinoma cases, and 30 endometrial endometrioid adenocarcinoma cases.
  • The rate of nodal endosalpingiosis was significantly higher in OSLMP cases (33%) compared with both cervical (0%, P<0.0001) and endometrial tumor cases (3%, P=0.0015).
  • [MeSH-minor] Female. Humans. Lymphatic Metastasis. Uterine Cervical Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871218.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Martínez-Palones JM, Gil-Moreno A, Pérez-Benavente MA, Garcia-Giménez A, Xercavins J: Umbilical metastasis after laparoscopic retroperitoneal paraaortic lymphadenectomy for cervical cancer: a true port-site metastasis? Gynecol Oncol; 2005 Apr;97(1):292-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Umbilical metastasis after laparoscopic retroperitoneal paraaortic lymphadenectomy for cervical cancer: a true port-site metastasis?
  • BACKGROUND: We present a case of umbilical metastasis after laparoscopic retroperitoneal paraaortic lymphadenectomy for cervical cancer.
  • CASE: A 59-year-old woman with stage IIIB cervical adenocarcinoma underwent laparoscopic paraaortic lymphadenectomy as well as a conventional laparoscopy to assess the presence of peritoneal carcinomatosis.
  • Seven months after completion of chemoradiotherapy, the patient presented a 2.5-cm umbilical tumor involving the trocar tract together with recurrence of the cervical mass.
  • Histological examination of the excised umbilical mass showed recurrence of the cervical adenocarcinoma, with strong peritumoral CD31 immunocytochemical expression.
  • [MeSH-major] Abdominal Neoplasms / secondary. Adenocarcinoma / secondary. Neoplasm Seeding. Umbilicus / pathology. Uterine Cervical Neoplasms / pathology


38. Yang Y, Chen L, Han BS, Xu CM, Pan HZ: [Construction and expression of various human prion proteins mutants with modified N-glycosylation sites in mammalian cells]. Sheng Wu Gong Cheng Xue Bao; 2006 May;22(3):373-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With site-direct mutation technique, human PRNP gene was mutated and the obtained mutants were subcloned into eukaryotic expressing plasmid pcDNA3.1 and transiently expressed in Hela cervical adenocarcinoma cell.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755913.001).
  • [ISSN] 1000-3061
  • [Journal-full-title] Sheng wu gong cheng xue bao = Chinese journal of biotechnology
  • [ISO-abbreviation] Sheng Wu Gong Cheng Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glycosylation End Products, Advanced; 0 / Mutant Proteins; 0 / Prions
  •  go-up   go-down


39. Yuan YV, Walsh NA: Antioxidant and antiproliferative activities of extracts from a variety of edible seaweeds. Food Chem Toxicol; 2006 Jul;44(7):1144-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dietary Laminaria and Porphyra sp. have been reported to reduce the risk of intestinal or mammary cancer in animal studies.
  • Thus, in the present study, we evaluated the effect of red alga, dulse (Palmaria palmata) and three kelp (Laminaria setchellii, Macrocystis integrifolia, Nereocystis leutkeana) extracts on human cervical adenocarcinoma cell line (HeLa cells) proliferation using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554116.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antioxidants; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols
  •  go-up   go-down


40. Ding DC, Hsu S, Chen SS, Hsu YH: Pap smears with reactive cellular changes: a prospective study. J Reprod Med; 2007 Oct;52(10):938-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine the prevalence of cervical dysplasia and cervical cancer in women with atypical squamous cells (ASCs).
  • The primary measurement was cervical dysplasia and the secondary one, cervical cancer.
  • RESULTS: Histologic results revealed normal findings in 30 (61%), mild dysplasia in 9 (18.3%), moderate dysplasia in 1 (2%), severe dysplasia in 2 (4%), squamous cell carcinoma in 2 (4%), adenocarcinoma in 1 (2%) and benign lesions in 4 (8.1%).
  • CONCLUSION: Among the subjects with cervical ASCs, 30% and 6% with cervical dysplasia and cervical cancer, respectively, were identified.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Uterine Cervical Dysplasia / epidemiology. Uterine Cervical Neoplasms / epidemiology
  • [MeSH-minor] Biopsy, Needle. Cervix Uteri / pathology. Colposcopy. Curettage. Female. Humans. Papanicolaou Test. Prevalence. Prospective Studies. Severity of Illness Index. Vaginal Smears


41. Roberts JM, Thurloe JK, Biro C, Hyne SG, Williams KE, Bowditch RC: Follow-up of cytologic predictions of endocervical glandular abnormalities: histologic outcomes in 123 cases. J Low Genit Tract Dis; 2005 Apr;9(2):71-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: We obtained histologic follow-up for 100% of 67 cytologic predictions of adenocarcinoma in situ (AIS) and 82% of 39 predictions of possible AIS (?AIS) made over a 4-year period (1999-2002) and for 25% of 105 atypical endocervical cells (AEC) predictions over a 12-month period (2000).
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma in Situ / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cervix Uteri / pathology. Cytodiagnosis / methods. Cytodiagnosis / standards. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Retrospective Studies. Vaginal Smears


42. Choi SJ, Brylev KA, Xu JZ, Mironov YV, Fedorov VE, Sohn YS, Kim SJ, Choy JH: Cellular uptake and cytotoxicity of octahedral rhenium cluster complexes. J Inorg Biochem; 2008 Nov;102(11):1991-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cellular uptake behavior of a novel class of octahedral rhenium cluster compounds, hexahydroxo complexes K(4)[{Re(6)S(8)}(OH)(6)].8H(2)O (1) and K(4)[{Re(6)Se(8)}(OH)(6)].8H(2)O (2), was evaluated in human cervical adenocarcinoma HeLa cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18783832.001).
  • [ISSN] 1873-3344
  • [Journal-full-title] Journal of inorganic biochemistry
  • [ISO-abbreviation] J. Inorg. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chelating Agents; 0 / Organometallic Compounds; 7440-15-5 / Rhenium
  •  go-up   go-down


43. Kim SS, Won SJ, Kim NJ, Yoo JK, Bae K, Lee KT: 3-Oxoolean-12-en-27-oic acid isolated from Aceriphyllum rossii induces caspase-8-dependent apoptosis in human promyelocytic leukemia HL-60 cells. Biol Pharm Bull; 2009 Jan;32(1):91-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 3-OA-treated HL-60 cells and HeLa human cervix adenocarcinoma cells displayed several apoptotic features, such as, DNA fragmentation, DNA laddering by agarose gel electrophoresis, and hypodiploid DNA contents by flow cytometry, and 3-OA also caused the activations of caspase-8, -9 and -3.

  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122287.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / FADD protein, human; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Fas-Associated Death Domain Protein; 0 / Neuroprotective Agents; 0 / RNA, Messenger; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Triterpenes; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 298-93-1 / thiazolyl blue; EC 3.4.21.- / HABP2 protein, human; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.22.- / Caspase 8
  •  go-up   go-down


44. Kasamatsu T, Onda T, Sasajima Y, Kato T, Ikeda S, Ishikawa M, Tsuda H: Prognostic significance of positive peritoneal cytology in adenocarcinoma of the uterine cervix. Gynecol Oncol; 2009 Dec;115(3):488-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of positive peritoneal cytology in adenocarcinoma of the uterine cervix.
  • OBJECTIVE: A retrospective analysis was carried out to evaluate the prognostic significance of peritoneal cytology in cervical adenocarcinoma.
  • METHODS: The records of 107 patients with FIGO stage IB to IIB cervical adenocarcinoma who underwent hysterectomy were reviewed.
  • Cox model analysis revealed positive cytology [hazards ratio (HR) 6.27, 95% confidence interval (CI) 2.13-18.41], positive lymph node (HR 6.20, 95% CI 1.87-20.57), ovarian metastasis (HR 5.20, 95% CI 1.18-22.82), and histological grade (HR 5.97, 95% CI 2.00-17.78) to be independent adverse risk factors for survival among the factors analyzed (lymph node status, lymph-vascular space invasion, tumor size, depth in cervical wall, pathological parametrial involvement, infiltration to vagina, ovarian metastasis, and histological grade).
  • CONCLUSION: The presence of positive peritoneal cytology appears to be an independent prognostic risk factor in patients with cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Peritoneal Cavity / pathology. Uterine Cervical Neoplasms / pathology


45. Niibe Y, Kenjo M, Onishi H, Ogawa Y, Kazumoto T, Ogino I, Tsujino K, Harima Y, Takahashi T, Anbai A, Tsuchida E, Toita T, Takemoto M, Yamashita H, Hayakawa K: High-dose-rate intracavitary brachytherapy combined with external beam radiotherapy for stage IIIb adenocarcinoma of the uterine cervix in Japan: a multi-institutional study of Japanese Society of Therapeutic Radiology and Oncology 2006-2007 (study of JASTRO 2006-2007). Jpn J Clin Oncol; 2010 Aug;40(8):795-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose-rate intracavitary brachytherapy combined with external beam radiotherapy for stage IIIb adenocarcinoma of the uterine cervix in Japan: a multi-institutional study of Japanese Society of Therapeutic Radiology and Oncology 2006-2007 (study of JASTRO 2006-2007).
  • OBJECTIVE: The current study was a retrospective questionnaire survey of stage IIIb adenocarcinoma of the uterine cervix treated with high-dose-rate intracavitary brachytherapy combined with external beam radiation therapy in Japan aimed to investigate the optimal dose on the basis of the biological effective dose and prognostic factors.
  • METHODS: Between 1990 and 2000, 61 patients with stage IIIb adenocarcinoma of the uterine cervix underwent high-dose-rate intracavitary brachytherapy combined with external beam radiation therapy in 19 major hospitals in Japan.
  • Fifty had only adenocarcinoma components and 11 had adenosquamous cell carcinoma components.
  • Stratified by histopathology, the 5-year overall survival rate was 22.1% for adenocarcinoma and 13.6% for adenosquamous cell carcinoma (P = 0.43).
  • CONCLUSIONS: The 5-year overall survival rate of stage IIIb adenocarcinoma of the uterine cervix in this retrospective questionnaire survey was 20.2%.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Carcinoma, Adenosquamous / radiotherapy. Uterine Cervical Neoplasms / radiotherapy


46. Bergauer F, Brüning A, Shabani N, Blankenstein T, Jückstock J, Dian D, Mylonas I: Inhibin/activin-betaE subunit in normal and malignant human cervical tissue and cervical cancer cell lines. J Mol Histol; 2009 Oct;40(5-6):353-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibin/activin-betaE subunit in normal and malignant human cervical tissue and cervical cancer cell lines.
  • Recently a novel beta subunit named betaE was described, although it is still unclear if normal or cancerous cervical epithelial cells as well as cervical cancer cell lines can synthesise the novel inhibin-betaE subunit.
  • About 4 normal cervical tissue samples together with 10 specimens of well-differentiated squamous cervical cancer and adenocarcinoma of the cervix were immunohistochemical analyzed.
  • Additionally, two cervical carcinoma cell lines (HeLa and CaSki) were analyzed by immunofluorescence and RT-PCR for the expression of this novel subunit.
  • We demonstrated for the first time an immunolabelling of the inhibin-betaE subunit in normal and malignant cervical tissue, as well as cervical cancer cells.
  • Although the physiological role is still quite unclear in cervical tissue, inhibin-betaE might play important roles in carcinogenesis.
  • Moreover, the synthesis of this subunit in cervical carcinoma cell lines of squamous and glandular epithelial origins also allows the use of these cell lines in elucidating its functions in cervical cancer pathogenesis.
  • However, since the expression of the inhibin-betaE is minimal in HeLa cells as assessed by immunofluorescence and RT-PCR, the CaSki cell line might be a better model for further functional experiments regarding cervical cancer pathogenesis.
  • [MeSH-major] Inhibin-beta Subunits / metabolism. Protein Subunits / metabolism. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Recent Prog Horm Res. 1988;44:1-34 [3064204.001]
  • [Cites] Histochem Cell Biol. 2009 Jul;132(1):33-8 [19363681.001]
  • [Cites] Mol Cell Endocrinol. 2002 Aug 30;194(1-2):117-22 [12242034.001]
  • [Cites] Arch Gynecol Obstet. 2005 Jun;272(1):59-66 [15309402.001]
  • [Cites] Eur J Cancer. 2009 May;45(7):1304-14 [19231155.001]
  • [Cites] Carcinogenesis. 2003 Nov;24(11):1801-9 [12949049.001]
  • [Cites] Acta Histochem. 2009;111(4):360-5 [19195690.001]
  • [Cites] Cancer Lett. 2007 Apr 28;249(1):14-7 [17320281.001]
  • [Cites] Oncol Rep. 2005 Jan;13(1):81-8 [15583806.001]
  • [Cites] Endocrinology. 2003 Aug;144(8):3497-504 [12865331.001]
  • [Cites] Hum Reprod Update. 2002 Nov-Dec;8(6):529-41 [12498423.001]
  • [Cites] Biochem Biophys Res Commun. 1995 May 16;210(2):581-8 [7755637.001]
  • [Cites] Gynecol Oncol. 2009 Aug;114(2):360-4 [19410282.001]
  • [Cites] Exp Biol Med (Maywood). 2002 Feb;227(2):75-87 [11815670.001]
  • [Cites] Endocr Rev. 2001 Dec;22(6):836-58 [11739336.001]
  • [Cites] Virology. 2009 Feb 20;384(2):260-5 [19135222.001]
  • [Cites] J Mol Endocrinol. 2002 Apr;28(2):137-48 [11932210.001]
  • [Cites] Int J Oncol. 2003 Jan;22(1):75-80 [12469187.001]
  • [Cites] Cytokine Growth Factor Rev. 2009 Apr;20(2):153-64 [19261538.001]
  • [Cites] Acta Histochem. 2009;111(4):366-71 [19195688.001]
  • [Cites] Stem Cells. 2005 Apr;23 (4):489-95 [15790770.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4A):1995-2000 [17649811.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] Biochim Biophys Acta. 1996 Jun 7;1307(2):145-8 [8679697.001]
  • [Cites] Arch Gynecol Obstet. 2010 Aug;282(2):185-91 [20012305.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1194-200 [9543140.001]
  • [Cites] Gynecol Oncol. 1998 Apr;69(1):23-31 [9570994.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Jan 17;206(2):608-13 [7826378.001]
  • [Cites] Acta Histochem. 2006;108(1):1-11 [16423381.001]
  • [Cites] Mutat Res. 2006 Nov-Dec;613(2-3):123-37 [16997617.001]
  • [Cites] Histochem Cell Biol. 2004 Nov;122(5):461-71 [15480736.001]
  • [Cites] J Mol Endocrinol. 2000 Jun;24(3):409-18 [10828834.001]
  • [Cites] Nature. 1992 Nov 26;360(6402):313-9 [1448148.001]
  • [Cites] Endocr J. 2005 Apr;52(2):169-75 [15863943.001]
  • [Cites] Cancer J. 2003 Sep-Oct;9(5):348-59 [14690309.001]
  • [Cites] Mol Cell Endocrinol. 2004 Oct 15;225(1-2):77-82 [15451571.001]
  • [Cites] Lancet. 2003 Jun 28;361(9376):2217-25 [12842378.001]
  • [Cites] Oncol Rep. 2007 Jan;17(1):97-104 [17143484.001]
  • [Cites] J Mol Histol. 2006 Jan;37(1-2):43-52 [16670820.001]
  • [Cites] Mol Cell Endocrinol. 2004 Oct 15;225(1-2):73-6 [15451570.001]
  • [Cites] Endocr Pathol. 2006 Spring;17(1):19-33 [16760577.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):6127-37 [10913194.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Nov 21;228(3):669-74 [8941337.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):96-103 [17909904.001]
  • (PMID = 20033758.001).
  • [ISSN] 1567-2387
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / INHBE protein, human; 0 / Protein Subunits; 93443-12-0 / Inhibin-beta Subunits
  •  go-up   go-down


47. Chuang LT, Lerner DL, Liu CS, Nezhat FR: Fertility-sparing robotic-assisted radical trachelectomy and bilateral pelvic lymphadenectomy in early-stage cervical cancer. J Minim Invasive Gynecol; 2008 Nov-Dec;15(6):767-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility-sparing robotic-assisted radical trachelectomy and bilateral pelvic lymphadenectomy in early-stage cervical cancer.
  • A combined pelvic lymphadenectomy with radical vaginal trachelectomy is an alternative to radical hysterectomy in the treatment of young women with cervical cancer desiring fertility preservation.
  • A 30-year-old woman, gravida 1, para 1, desiring fertility preservation was given the diagnosis of invasive adenocarcinoma on cervical cone excision.
  • We hope robotic-assisted radical trachelectomy will become an option for select women with early-stage cervical cancer who desire fertility preservation.
  • [MeSH-major] Adenocarcinoma / surgery. Fertility / physiology. Lymph Node Excision / methods. Robotics. Uterine Cervical Neoplasms / surgery


48. Lee JW, Park JA, Kim SH, Seo JH, Lim KJ, Jeong JW, Jeong CH, Chun KH, Lee SK, Kwon YG, Kim KW: Protein kinase C-delta regulates the stability of hypoxia-inducible factor-1 alpha under hypoxia. Cancer Sci; 2007 Sep;98(9):1476-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present article protein kinase C-delta (PKC-delta) is activated by hypoxia, increases the protein stability and transcriptional activity of HIF-1alpha in human cervical adenocarcinoma cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17608772.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; EC 2.7.11.13 / Protein Kinase C-delta
  •  go-up   go-down


49. Sharpless KE, Schnatz PF, Mandavilli S, Greene JF, Sorosky JI: Dysplasia associated with atypical glandular cells on cervical cytology. Obstet Gynecol; 2005 Mar;105(3):494-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysplasia associated with atypical glandular cells on cervical cytology.
  • Most women aged younger than 35 years had a squamous abnormality, whereas women aged 35 years or older had a greater diversity of squamous and glandular lesions and accounted for all cases of endometrial cancer, adenocarcinoma in situ, and cervical adenocarcinoma.
  • [MeSH-major] Cervix Uteri / pathology. Uterine Cervical Dysplasia / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / pathology. Female. Humans. Middle Aged. Uterine Cervical Neoplasms / pathology. Vaginal Smears


50. O'Neill CJ, McCluggage WG: p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol; 2006 Jan;13(1):8-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 expression in the female genital tract and its value in diagnosis.
  • Diffuse (as opposed to focal) positivity with p16 in the cervix can be regarded as a surrogate marker of the presence of high-risk human papillomavirus (HPV).
  • In cervical squamous lesions, p16 is positive in most high-grade cervical intraepithelial neoplasia (CIN) and in some cases of low-grade CIN, usually those associated with high-risk HPV. p16 may be useful to identify small focal high-grade CIN lesions, to distinguish some cases of CIN involving immature metaplastic squamous epithelium from immature metaplastic squamous epithelium not involved by CIN and to distinguish high-grade CIN from benign mimics.
  • Most cervical carcinomas of squamous, glandular, and small cell type are p16-positive.
  • In cervical glandular lesions, p16 is useful, as part of a panel, in the distinction between adenocarcinoma in situ (diffusely positive) and benign mimics, including tuboendometrial metaplasia and endometriosis, which are usually p16-negative or focally positive. p16 may be used, in combination with other markers, to distinguish between a cervical adenocarcinoma (diffuse positivity) and an endometrioid-type endometrial adenocarcinoma (negative or focally positive).
  • Some uterine serous carcinomas are diffusely positive.
  • In the uterus, p16 positivity is more common and widespread in leiomyosarcomas than leiomyomas, and this may be a useful aid to diagnosis, although problematic uterine smooth muscle neoplasms have not been extensively studied.
  • Metastatic cervical adenocarcinomas in the ovary are usually diffusely p16-positive, and because these may closely mimic a primary ovarian endometrioid or mucinous adenocarcinoma, this may be a valuable diagnostic aid, although p16 expression in primary ovarian adenocarcinomas of these morphologic subtypes has not been widely investigated.
  • Some ovarian serous carcinomas, similar to their uterine counterparts, are p16-positive.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / analysis. Genital Neoplasms, Female / diagnosis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Carcinoma, Small Cell / chemistry. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / genetics. Cystadenocarcinoma, Serous / chemistry. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / genetics. Diagnosis, Differential. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / genetics. Female. Genes, p16. Genitalia, Female / chemistry. Genitalia, Female / physiopathology. Humans. Immunohistochemistry. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / genetics. Tumor Suppressor Proteins / analysis. Tumor Suppressor Proteins / genetics. Uterine Cervical Neoplasms / chemistry. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / genetics. Uterine Neoplasms / chemistry. Uterine Neoplasms / diagnosis. Uterine Neoplasms / genetics. Vulvar Neoplasms / chemistry. Vulvar Neoplasms / classification. Vulvar Neoplasms / diagnosis. Vulvar Neoplasms / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462152.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Proteins
  • [Number-of-references] 65
  •  go-up   go-down


51. Luciani S, Bertoletti L, Vergnon JM: [Endoscopic treatment of endobronchial metastases from adenocarcinoma of the uterine cervix]. Rev Mal Respir; 2010 Sep;27(7):759-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoscopic treatment of endobronchial metastases from adenocarcinoma of the uterine cervix].
  • [Transliterated title] Traitement endoscopique de métastases endobronchiques d'un adénocarcinome du col utérin.
  • They are very rarely due to uterine cervical cancer.
  • CASE REPORT: We present the extraordinary case of a woman with endobronchial metastases from an adenocarcinoma of the uterine cervix.
  • Pathological analysis of this tumour confirmed the diagnosis and found papilloma virus infection.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Bronchial Neoplasms / secondary. Bronchial Neoplasms / surgery. Bronchoscopy. Uterine Cervical Neoplasms / pathology


52. Nishida M, Nasu K, Takai N, Miyakawa I, Kashima K: Adenoid cystic carcinoma of the uterine cervix. Int J Clin Oncol; 2005 Jun;10(3):198-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of the uterine cervix.
  • Adenoid cystic carcinoma of the uterine cervix is a rare and peculiar variant of adenocarcinoma.
  • This tumor represents 3% of all primary cervical adenocarcinomas, and it is locally aggressive and capable of metastasis to other organs even in its early stage.
  • Generally, radiotherapy and chemotherapy are chosen as the first treatment, because this cancer is seen most commonly in the elderly.
  • [MeSH-major] Carcinoma, Adenoid Cystic / radiotherapy. Uterine Cervical Neoplasms / radiotherapy


53. Jung YW, Kim SW, Kim S, Kim JH, Cho NH, Kim JW, Kim YT: Prevalence and clinical relevance of cyclooxygenase-1 and -2 expression in stage IIB cervical adenocarcinoma. Eur J Obstet Gynecol Reprod Biol; 2010 Jan;148(1):62-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and clinical relevance of cyclooxygenase-1 and -2 expression in stage IIB cervical adenocarcinoma.
  • OBJECTIVE: The objective of this study was to determine the relationship between cyclooxygenase (COX)-1 and -2 and prognosis in patients diagnosed with FIGO stage IIB cervical adenocarcinoma who underwent concurrent chemoradiotherapy.
  • STUDY DESIGN: Twenty-three patients diagnosed with stage IIB cervical adenocarcinoma and treated with concurrent chemoradiotherapy between 1990 and 1995 were included in this study.
  • COX-2 expression was associated with poor response to treatment and cancer-related death (P=0.043 and 0.012, respectively).
  • CONCLUSION: Only COX-2 was found to be a potent prognostic factor in patients treated with concurrent chemoradiotherapy for stage IIB cervical adenocarcinoma.
  • However, further studies with more samples are needed to definitely demonstrate the relationship between COX expression and cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Cyclooxygenase 1 / biosynthesis. Cyclooxygenase 2 / biosynthesis. Uterine Cervical Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19836124.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


54. Pukkala E, Malila N, Hakama M: Socioeconomic differences in incidence of cervical cancer in Finland by cell type. Acta Oncol; 2010;49(2):180-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Socioeconomic differences in incidence of cervical cancer in Finland by cell type.
  • INTRODUCTION: We studied variation in incidence of cervix cancer during 1971-1995 among Finnish women born in 1906 to 1945 by social class and cell type.
  • MATERIAL AND METHODS: The Finnish Cancer Registry data were linked to the 1970 Population Census, which included social class data.
  • There were 0.8 million individuals in the cohort under follow-up, with 5,102 squamous cell cancers and 573 cases of cervical adenocarcinoma diagnosed after the census date.
  • RESULTS: Incidence of squamous cell cancer was more than two-fold in the lowest social class (standardized incidence ratio (SIR) 1.29, 95% CI 1.21-1.36) as compared with the highest one (SIR 0.59, 0.51-0.66), while there was no association between social class and risk on adenocarcinoma (SIR 1.07, 0.87-1.28 and 1.08, 0.79-1.45, respectively).
  • DISCUSSION: Oncogenic HPV is regarded as the necessary cause of all types of cervix cancer.
  • Lack of association between adenocarcinoma and social class makes the HPV-etiology of this cell type less credible than that of squamous cell cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Uterine Cervical Neoplasms / epidemiology


55. Numnum TM, Makhija S, Lu B, Wang M, Rivera A, Stoff-Khalili M, Alvarez RD, Zhu ZB, Curiel DT: Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines. Gynecol Oncol; 2008 Jan;108(1):34-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hec1 (Highly Expressed in Cancer gene 1) has recently been shown to play an important role in the proper segregation of chromosomes during mitosis.
  • Recently, an adenovirus delivery system carrying RNA interference (RNAi) of Hec1 has been reported in a cervical adenocarcinoma model.
  • METHODS: Two adenoviruses (Ad-siRNA-Hec1 and Ad-siRNA-Hec1.F5/3), along with a negative control (Ad-siRNA-GAPDH.F5/3), were created using homologous recombination.
  • RESULTS: QPCR demonstrated a 2-log viral infectivity enhancement with Ad-siRNA-Hec1.F5/3 over Ad-siRNA-Hec1.
  • QPCR at 72 h revealed mRNA knockdown induced by Ad-siRNA-Hec1 and Ad-siRNA-Hec1.F5/3 in SKOV3.ip1 and HEY cells, respectively (71%/60%, and 32%/78% mRNA knockdown compared to negative control).
  • Western blot revealed translational inhibition induced by both Hec1 Ads with the least knockdown seen with Ad-siRNA-GAPDH.F5/3.
  • MTS assay indicated increased cell death 8 days post-infection with Ad-siRNA-Hec1 and Ad-siRNA-Hec1.F5/3 in SKOV3.ip1 and HEY cell lines, respectively (75% vs. 35% and 43% vs. 12% viable cells).
  • Crystal violet staining revealed increased cell death with Ad-siRNA-Hec1.F5/3 in all tested cell lines.
  • The infectivity-enhanced adenovirus as delivery mechanism shows potential application in future gene therapy models of RNAi in ovarian cancer.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Ther. 2003 Sep;8(3):449-58 [12946318.001]
  • [Cites] Mol Ther. 2003 Nov;8(5):762-8 [14599809.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):4339-45 [14625284.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Aug;40(4):342-8 [15188458.001]
  • [Cites] Mol Ther. 2004 Jul;10(1):162-71 [15233951.001]
  • [Cites] Mol Cancer Ther. 2004 Jul;3(7):833-8 [15252144.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):785-95 [15350374.001]
  • [Cites] J Virol. 1968 May;2(5):430-9 [4301313.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2088-95 [12727824.001]
  • [Cites] Curr Biol. 2003 Jan 8;13(1):41-6 [12526743.001]
  • [Cites] Science. 2002 Sep 27;297(5590):2267-70 [12351790.001]
  • [Cites] Mol Ther. 2001 Jan;3(1):28-35 [11162308.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):244-51 [12110901.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7297-301 [7638184.001]
  • [Cites] Genes Dev. 1999 Dec 15;13(24):3191-7 [10617568.001]
  • [Cites] Gene Ther. 1997 Sep;4(9):961-8 [9349433.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):806-11 [9486653.001]
  • [Cites] Cancer Gene Ther. 1999 Jul-Aug;6(4):367-72 [10419055.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):341-8 [15661219.001]
  • [Cites] Mol Biol Cell. 2005 Feb;16(2):519-31 [15548592.001]
  • [Cites] Gene Ther. 2006 Jan;13(1):1-7 [16121206.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8829-36 [16361572.001]
  • [Cites] Mol Biol Rep. 2006 Mar;33(1):43-9 [16636916.001]
  • [Cites] Br J Cancer. 2006 May 8;94(9):1300-10 [16622456.001]
  • [Cites] Int J Oncol. 2006 Sep;29(3):595-603 [16865275.001]
  • [Cites] Int J Oncol. 2006 Nov;29(5):1319-29 [17016667.001]
  • [Cites] Curr Oncol Rep. 2006 Nov;8(6):441-7 [17040622.001]
  • [Cites] Cancer Biol Ther. 2006 Dec;5(12):1708-13 [17106249.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(14):1917-26 [12204675.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):275-80 [11801569.001]
  • (PMID = 18061250.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA083821-08; United States / NCI NIH HHS / CA / R01 CA083821; United States / NCI NIH HHS / CA / R01 CA083821-08
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NDC80 protein, human; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering
  • [Other-IDs] NLM/ NIHMS38788; NLM/ PMC2744403
  •  go-up   go-down


56. Coupienne I, Piette J, Bontems S: How to monitor NF-kappaB activation after photodynamic therapy. Methods Mol Biol; 2010;635:79-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For several years, photodynamic therapy (PDT) has emerged as an attractive alternative approach for the treatment of different affections involving various forms of cancer and an increasing number of reports have highlighted the activation of the NF-kappaB following PDT treatment.
  • As a working model we will present results obtained from a 5-aminolevulinic acid-PDT treatment on cervix adenocarcinoma cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552341.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / I-kappa B Proteins; 0 / NF-kappa B; 0 / Photosensitizing Agents; 0 / Synaptotagmin I; 139874-52-5 / NF-kappaB inhibitor alpha; 88755TAZ87 / Aminolevulinic Acid; EC 1.13.12.- / Luciferases
  •  go-up   go-down


57. Favero G, Lanowska M, Schneider A, Marnitz S, Köhler C: Laparoscopic pelvic lymphadenectomy in a patient with cervical cancer stage Ib1 complicated by a twin pregnancy. J Minim Invasive Gynecol; 2010 Jan-Feb;17(1):118-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic pelvic lymphadenectomy in a patient with cervical cancer stage Ib1 complicated by a twin pregnancy.
  • Cervical cancer is the most frequently observed malignancy during pregnancy.
  • To our knowledge, this is the first report of a twin pregnancy complicated by cancer of the uterine cervix that was successfully treated with laparoscopic pelvic lymphadenectomy and subsequently with neoadjuvant chemotherapy.
  • Cervical adenocarcinoma, grade 2, stage 1b1 with lymphovascular space invasion was diagnosed.
  • [MeSH-major] Adenocarcinoma / surgery. Lymph Node Excision. Pregnancy Complications, Neoplastic / surgery. Pregnancy, Multiple. Uterine Cervical Neoplasms / surgery


58. Alpan AS, Zencir S, Zupkó I, Coban G, Réthy B, Gunes HS, Topcu Z: Biological activity of bis-benzimidazole derivatives on DNA topoisomerase I and HeLa, MCF7 and A431 cells. J Enzyme Inhib Med Chem; 2009 Jun;24(3):844-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The compounds were screened via in vitro plasmid superciol relaxation assays using mammalian DNA topoisomerase I and cytostatic assays were carried out against HeLa (cervix adenocarcinoma), MCF7 (breast adenocarcinoma) and A431 (skin epidermoid carcinoma) cells for selected derivatives.
  • [MeSH-minor] Animals. Breast Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Cell Line, Tumor. DNA Topoisomerases, Type I / metabolism. Female. HeLa Cells. Humans. Spectrum Analysis. Structure-Activity Relationship. Uterine Cervical Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18951286.001).
  • [ISSN] 1475-6374
  • [Journal-full-title] Journal of enzyme inhibition and medicinal chemistry
  • [ISO-abbreviation] J Enzyme Inhib Med Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzimidazoles; 0 / Topoisomerase I Inhibitors; 16656-27-2 / bis-benzimidazole; EC 5.99.1.2 / DNA Topoisomerases, Type I
  •  go-up   go-down


59. Zhao Y, Lin H, Shen D, Xuan Y, Lin Z: Distribution of HPV genotypes in uterine cervical lesions in Yanbian, northern China. Pathol Int; 2008 Oct;58(10):643-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of HPV genotypes in uterine cervical lesions in Yanbian, northern China.
  • The aim of the present study was to investigate the distribution of HPV genotypes in uterine cervical lesions in Yanbian, northern China.
  • HPV-DNA chip (oligonucleotide microarray) and cervical biopsy were used for 322 women in 1998-2005.
  • All the normal cervical epithelia were negative for HPV.
  • The positive rate of high-risk HPV was 33.9% in cervical intra-epithelial neoplasia (CIN)-1, 51.6% in CIN-2, 57.7% in CIN-3, 66.7% in cervical glandular intra-epithelial neoplasia (CGIN), 91.7% in squamous cell carcinoma (SCC), and 78.6% in adenocarcinoma.
  • HPV-16 was the major type in all CIN and SCC cervical lesions, but in cervical adenocarcinoma HPV-18 was the most common type, and HPV-16 was the second most common type.
  • Several cases of CIN-3, SCC and adenocarcinoma had multiple types of HPV, but there was none in CIN-1/2.
  • In summary, HPV-16 is the type most frequently involved in the development of SCC of the cervix, and this may be helpful for the prediction of the development and progress of CIN-2/3, whereas both HPV-18 and -16 play a prominent role in the development of adenocarcinoma and CGIN of the cervix in Yanbian, northern China.
  • [MeSH-major] Adenocarcinoma / virology. Alphapapillomavirus / genetics. Carcinoma, Squamous Cell / virology. Cervical Intraepithelial Neoplasia / virology. Papillomavirus Infections / virology. Uterine Cervical Neoplasms / virology


60. Brink AA, Zielinski GD, Steenbergen RD, Snijders PJ, Meijer CJ: Clinical relevance of human papillomavirus testing in cytopathology. Cytopathology; 2005 Feb;16(1):7-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer of the uterine cervix is the second most common cancer in women worldwide.
  • Currently, cervical screening is based on cytology alone.
  • Because infection with high-risk human papillomavirus types (hrHPVs) is a necessary cause of cervical cancer, it has been postulated that screening might become more efficient when it is based on combined cytology and hrHPV testing.
  • In this review we will discuss the advantages of added HPV tests in cervical cancer screening, as a quality control for false-negative smears, in triage of women with equivocal smears, in follow-up of women treated for CIN3 or cervical cancer and for the detection of cervical adenocarcinoma.
  • [MeSH-major] Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis. Vaginal Smears
  • [MeSH-minor] Adenocarcinoma / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / therapy. Cytodiagnosis / methods. False Negative Reactions. Female. Humans. Mass Screening. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cytopathology. 2005 Feb;16(1):3-6 [15859308.001]
  • (PMID = 15859309.001).
  • [ISSN] 0956-5507
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 50
  •  go-up   go-down


61. Tian Q, Lu W, Chen H, Ye F, Xie X: The nonsynonymous single-nucleotide polymorphisms in codon 31 of p21 gene and the susceptibility to cervical cancer in Chinese women. Int J Gynecol Cancer; 2009 Aug;19(6):1011-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The nonsynonymous single-nucleotide polymorphisms in codon 31 of p21 gene and the susceptibility to cervical cancer in Chinese women.
  • BACKGROUND: It was suggested that single-nucleotide polymorphisms in p21 codon 31 seem to be associated with a variety of human malignancies; very few studies have focused on the association between p21 codon 31 polymorphisms and cervical cancer.
  • This study explored whether p21 codon 31 nonsynonymous single-nucleotide polymorphisms might be associated with an increased risk of cervical cancer development among Chinese women.
  • METHODS: Peripheral blood samples were obtained from patients with cervical cancer (n = 317) and healthy controls (n = 353) for detecting the biallelic polymorphisms at codon 31 of p21 gene by the mismatch amplification mutation assay-polymerase chain reaction.
  • Cervix brush-off samples were obtained from patients with cervical squamous cell carcinoma (SCC) and controls for detection of high-risk human papillomavirus (HR-HPV).
  • RESULTS: The AGA (Arg) allele frequency in patients with cervical SCCs was significantly higher than that in controls.
  • AGA/AGA and AGA/AGC genotypes were more frequently found in cervical SCCs than in controls.
  • There was no significant difference of allele frequency or genotype distribution between cervical adenocarcinomas and controls, or between HR-HPV-positive and HR-HPV-negative groups.
  • CONCLUSIONS: p21 Codon 31 with AGA (Arg) allele is a genetic risk factor of cervical SCC, and the increased risk is probably not caused by increasing host susceptibility to HR-HPV infection.
  • [MeSH-major] Asian Continental Ancestry Group / genetics. Carcinoma, Squamous Cell / genetics. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Polymorphism, Single Nucleotide. Uterine Cervical Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Case-Control Studies. Female. Gene Frequency. Genetic Predisposition to Disease. Genotype. Humans. Mutation, Missense / physiology. Papillomavirus Infections / complications

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820361.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21
  •  go-up   go-down


62. Hussain SK, Sundquist J, Hemminki K: Familial clustering of cancer at human papillomavirus-associated sites according to the Swedish Family-Cancer Database. Int J Cancer; 2008 Apr 15;122(8):1873-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial clustering of cancer at human papillomavirus-associated sites according to the Swedish Family-Cancer Database.
  • Familial aggregation of cervical cancer has been demonstrated previously, however aggregation of other human papillomavirus-associated anogenital, upper aerodigestive tract and skin cancers has not been fully characterized.
  • The Swedish Family-Cancer Database, which contains reliable data on cancer incidence and nuclear family linkages for all residents of Sweden between 1958 and 2004, was used to calculate standardized incidence ratios (SIR) and 95% confidence intervals for offspring site-specific cancer risks according to site-specific cancer in sibling and parental probands.
  • Offspring cancer risk was significantly increased when either a sibling or parent was affected at the same site for penile squamous cell carcinoma (SCC, SIR = 7.54), cervical adenocarcinoma (AC, SIR = 2.31), vulvar SCC (SIR = 2.27), skin SCC (SIR = 2.14), rectal AC (SIR = 1.86), in situ cervical SCC (SIR = 1.80), invasive cervical SCC (SIR = 1.77) and upper aerodigestive tract SCC (SIR = 1.57).
  • In situ cervical SCC risk in offspring was strongly influenced by siblings affected with oropharyngeal SCC (SIR = 3.17) and tonsillar SCC (SIR = 1.84).
  • Familial skin SCC was largely unassociated with anogenital or upper aerodigestive tract cancer risk in offspring.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adult. Aged. Anus Neoplasms / epidemiology. Carcinoma in Situ / epidemiology. Carcinoma, Squamous Cell / epidemiology. Cluster Analysis. Family. Female. Humans. Incidence. Male. Medical Record Linkage. Middle Aged. Mouth Neoplasms / epidemiology. Odds Ratio. Papillomavirus Infections / complications. Papillomavirus Infections / virology. Pharyngeal Neoplasms / epidemiology. Registries. Sweden / epidemiology. Tonsillar Neoplasms / epidemiology. Tumor Virus Infections / complications. Tumor Virus Infections / virology. Uterine Cervical Neoplasms / epidemiology. Vulvar Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18074353.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Kawauchi S, Kusuda T, Liu XP, Suehiro Y, Kaku T, Mikami Y, Takeshita M, Nakao M, Chochi Y, Sasaki K: Is lobular endocervical glandular hyperplasia a cancerous precursor of minimal deviation adenocarcinoma?: a comparative molecular-genetic and immunohistochemical study. Am J Surg Pathol; 2008 Dec;32(12):1807-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is lobular endocervical glandular hyperplasia a cancerous precursor of minimal deviation adenocarcinoma?: a comparative molecular-genetic and immunohistochemical study.
  • Although lobular endocervical glandular hyperplasia (LEGH) was originally described as a distinct hyperplastic glandular lesion of the uterine cervix, recent studies have raised a question that LEGH may be a cancerous precursor of minimal deviation adenocarcinoma (MDA) and other mucinous adenocarcinomas (MACs) of the uterine cervix.
  • Dual-color fluorescence in situ hybridization confirmed a gain of chromosome 3 fragment in these cervical glandular lesions.
  • Microsatellite instability was rarely detected in these cervical glandular lesions.
  • Our present study results demonstrated a molecular-genetic link between LEGH and cervical mucinous glandular malignancies including MDA and MAC, and are thought to support the hypothesis that a proportion of LEGHs are cancerous precursors of MDA and/or MAC.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Precancerous Conditions / pathology. Uterine Cervical Neoplasms / pathology


64. Niibe Y, Hayakawa K, Kanai T, Tsunoda S, Arai M, Jobo T, Kuramoto H, Unno N: Optimal dose for stage IIIB adenocarcinoma of the uterine cervix on the basis of biological effective dose. Eur J Gynaecol Oncol; 2006;27(1):47-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal dose for stage IIIB adenocarcinoma of the uterine cervix on the basis of biological effective dose.
  • PURPOSE: Prognosis of uterine cervical adenocarcinoma in locally advanced stage treated with radiation therapy has been considered to be much worse than that of squamous cell carcinoma because the optimal dose for the former one has not been determined.
  • Thus, the current study was performed to investigate the optimal dose for Stage IIIB, locally advanced stage, adenocarcinoma of the uterine cervix on the basis of the biological effective dose (BED).
  • METHODS: One-hundred and seventy-nine patients with Stage IIIB carcinoma of the uterine cervix were treated with curative intended therapy at Kitasato University Hospital between 1976 and 2000.
  • Out of them, 13 patients had an adenocarcinoma component in pathological findings.
  • Nine patients were diagnosed with adenocarcinoma and four patients were diagnosed with adenosquamous cell carcinoma.
  • CONCLUSION: The current study suggested that the optimal dose for Stage IIIB adenocarcinoma of the uterine cervix might be T-BED10 > or = 100 Gy.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Radiotherapy, High-Energy / methods. Salvage Therapy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / radiotherapy


65. Twu NF, Yuan CC, Yen MS, Lai CR, Chao KC, Wang PH, Wu HH, Chen YJ: Expression of Aurora kinase A and B in normal and malignant cervical tissue: high Aurora A kinase expression in squamous cervical cancer. Eur J Obstet Gynecol Reprod Biol; 2009 Jan;142(1):57-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Aurora kinase A and B in normal and malignant cervical tissue: high Aurora A kinase expression in squamous cervical cancer.
  • However, the expression of Aurora kinases in normal and neoplastic cervical tissues remains undetermined.
  • STUDY DESIGN: Immunohistochemical expression of Aurora A and B kinase was examined in 20 normal cervix, 35 cervical intraepithelial neoplasm 3 (CIN 3) and 95 cervical cancers, including squamous cell carcinoma (SCC) (n=76) and adenocarcinoma (AC) (n=19).
  • RESULTS: The Aurora A and B expression was significantly increased in carcinoma and CIN 3, compared with normal cervix.
  • However, expression of Aurora A and B showed no significant correlation between CIN 3 and cervical cancer.
  • Based on the results of this study, it would be interesting to know whether Aurora kinases play a role in pathogenesis of cervical dysplasia and SCC patients.
  • [MeSH-major] Carcinoma, Squamous Cell / enzymology. Cervix Uteri / enzymology. Protein-Serine-Threonine Kinases / biosynthesis. Uterine Cervical Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aurora Kinase A. Aurora Kinase B. Aurora Kinases. Cervical Intraepithelial Neoplasia / enzymology. Female. Gene Expression. Humans. Kaplan-Meier Estimate. Middle Aged


66. Brown AK, Gillis S, Deuel C, Angel C, Glantz C, Dubeshter B: Abnormal cervical cytology: a risk factor for endometrial cancer recurrence. Int J Gynecol Cancer; 2005 May-Jun;15(3):517-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal cervical cytology: a risk factor for endometrial cancer recurrence.
  • The objective of this study was to evaluate the relationship between cervical cytology, histologic type, and risk of endometrial cancer recurrence.
  • Risk factors for recurrence including histology, tumor grade, nodal status, myometrial invasion, peritoneal washings, stage, and cervical cytology were assessed.
  • Abnormal cervical cytology was defined as the presence of any endometrial cells on Pap smear.
  • Thirty-nine (9%) patients developed recurrent endometrial cancer.
  • For endometrioid adenocarcinoma, abnormal cervical cytology occurred in 61% and 7% recurred, while with high-risk histologies, 84% had abnormal cervical cytology and 19% recurred (P < 0.05).
  • Abnormal cervical cytology is associated with increased risk of endometrial cancer recurrence.
  • Abnormal cervical cytology occurs more frequently in high-risk histologies, which are known to have a higher risk of recurrence.
  • [MeSH-major] Carcinoma / pathology. Cervix Uteri / pathology. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local. Papanicolaou Test. Vaginal Smears


67. El-Ghobashy AA, Shaaban AM, Innes J, Prime W, Herrington CS: Differential expression of cyclin-dependent kinase inhibitors and apoptosis-related proteins in endocervical lesions. Eur J Cancer; 2007 Sep;43(13):2011-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, a panel of cyclin-dependent kinase inhibitors (CDKIs) and apoptosis-related proteins (p16, p21, p53, Bcl2 and hsp27) was analysed by immunohistochemistry in 91 glandular cervical lesions.
  • A significant increase in p21 and p53 expression occurred from normal cervix (n=11) through endometriosis/tubo-endometrioid metaplasia (TEM) (n=19) and cervical glandular intraepithelial neoplasia (CGIN)/adenocarcinoma in situ (AIS) (n=33) to invasive adenocarcinoma (n=28).
  • p16 showed diffuse strong expression in CGIN/AIS and invasive adenocarcinoma compared with focal expression in some TEM/endometriosis lesions and no expression in normal cervix.
  • Bcl2 was highly expressed in TEM/endometriosis compared with CGIN/AIS and adenocarcinoma. p16 immunostaining discriminated accurately between neoplastic and non-neoplastic cervical lesions, provided that diffuse strong positivity was present.
  • These data demonstrate that analysis of CDKIs and apoptosis-related proteins provides useful information in the diagnostic assessment of glandular lesions of the cervix.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Cervix Uteri / metabolism. Cyclin-Dependent Kinase Inhibitor Proteins / metabolism. Uterine Cervical Neoplasms / metabolism


68. Chaturvedi AK, Kleinerman RA, Hildesheim A, Gilbert ES, Storm H, Lynch CF, Hall P, Langmark F, Pukkala E, Kaijser M, Andersson M, Fossa SD, Joensuu H, Travis LB, Engels EA: Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix. J Clin Oncol; 2009 Feb 20;27(6):967-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix.
  • PURPOSE: Although cervical squamous cell carcinoma (SCC) and adenocarcinoma (AC) are both caused by human papillomavirus (HPV) infection, they differ in cofactors such as cigarette smoking.
  • We assessed whether these cofactor differences translate into differences in second cancer risk.
  • PATIENTS AND METHODS: We assessed second cancer risk among 85,109 cervical SCC and 10,280 AC survivors reported to population-based cancer registries in Denmark, Finland, Norway, Sweden, and the United States.
  • RESULTS: Overall cancer risk was significantly increased among both cervical SCC survivors (n = 10,559 second cancers; SIR, 1.31; 95% CI, 1.29 to 1.34) and AC survivors (n = 920 second cancers; SIR, 1.29; 95% CI, 1.22 to 1.38).
  • Risks of HPV-related and radiation-related cancers were increased to a similar extent among cervical SCC and AC survivors.
  • Although significantly increased in both groups when compared with the general population, risk of smoking-related cancers was significantly higher among cervical SCC than AC survivors (P = .015; SIR for cervical SCC = 2.07 v AC = 1.78).
  • This difference was limited to lung cancer (SIR for cervical SCC = 2.69 v AC = 2.18; P = .026).
  • The increased lung cancer risk among cervical AC survivors was observed for both lung SCC and lung AC.
  • SIRs for second cancers of the colon, soft tissue, melanoma, and non-Hodgkin's lymphoma were significantly higher among cervical AC than SCC survivors.
  • CONCLUSION: The second cancer profiles among cervical SCC and AC survivors mirror the similarities and differences in cofactors for these two histologies.
  • Because smoking is not a cofactor for cervical AC, the increased lung cancer risk suggests a role for additional factors.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2001 Feb;12(2):153-61 [11246844.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1611-22 [18628412.001]
  • [Cites] Lancet. 2002 Mar 30;359(9312):1093-101 [11943256.001]
  • [Cites] J Clin Pathol. 2002 Dec;55(12):885-91 [12461047.001]
  • [Cites] Int J Cancer. 2003 Jul 10;105(5):687-91 [12740919.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):57-65 [12807947.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):814-21 [12910527.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2078-86 [14647141.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):1035-44 [14983500.001]
  • [Cites] Br J Cancer. 2004 May 4;90(9):1787-91 [15150591.001]
  • [Cites] Cancer. 2004 Sep 15;101(6):1428-36 [15368331.001]
  • [Cites] J Epidemiol Community Health. 1984 Mar;38(1):85-8 [6707569.001]
  • [Cites] J Natl Cancer Inst. 1985 May;74(5):955-75 [3858584.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):679-88 [3338033.001]
  • [Cites] Gynecol Oncol. 1989 May;33(2):189-92 [2703179.001]
  • [Cites] Gynecol Oncol. 1989 Jun;33(3):340-3 [2722061.001]
  • [Cites] Int J Cancer. 1989 Jul 15;44(1):7-16 [2744900.001]
  • [Cites] Laryngoscope. 1992 Jan;102(1):9-13 [1309932.001]
  • [Cites] Gynecol Oncol. 1993 Dec;51(3):301-6 [8112636.001]
  • [Cites] Cancer. 1995 Aug 1;76(3):442-52 [8625126.001]
  • [Cites] Invest Radiol. 1995 Dec;30(12):724-9 [8748186.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 2:S3-9 [15552776.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2191-9 [16172231.001]
  • [Cites] Lung Cancer. 2006 Jan;51(1):21-9 [16337709.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1481-95 [16206285.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):292-3 [16507820.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):303-15 [16507827.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25 [16949997.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/35-41 [16950016.001]
  • [Cites] Int J Cancer. 2007 May 15;120(10):2214-20 [17278095.001]
  • [Cites] Br J Cancer. 2007 Jul 2;97(1):85-91 [17579626.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4C):2697-704 [17695435.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 7;99(21):1634-43 [17971527.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10686-93 [18006810.001]
  • [CommentIn] J Clin Oncol. 2009 Jun 20;27(18):3065-6; author reply 3066-7 [19433676.001]
  • (PMID = 19114696.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2738433
  •  go-up   go-down


69. Lavie O, Segev Y, Peer G, Gutterman E, Sagie S, Auslnader R: Conservative management for villoglandular papillary adenocarcinoma of the cervix diagnosed during pregnancy followed by a successful term delivery: a case report and a review of the literature. Eur J Surg Oncol; 2008 May;34(5):606-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative management for villoglandular papillary adenocarcinoma of the cervix diagnosed during pregnancy followed by a successful term delivery: a case report and a review of the literature.
  • [MeSH-major] Adenocarcinoma, Papillary / surgery. Conization. Pregnancy Complications, Neoplastic / surgery. Uterine Cervical Neoplasms / surgery


70. Othumpangat S, Kashon M, Joseph P: Sodium arsenite-induced inhibition of eukaryotic translation initiation factor 4E (eIF4E) results in cytotoxicity and cell death. Mol Cell Biochem; 2005 Nov;279(1-2):123-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure to arsenic (As) is a risk factor for the development of diabetes, vascular diseases and cancer.
  • We have also investigated the potential cellular mechanisms underlying the As-induced de-regulation of expression of eIF4E that are most likely responsible for the cytotoxicity and cell death induced by As.
  • Exposure of four different human cell lines - HCT15 (colorectal adenocarcinoma), PLC/PR/5 (hepatocellular carcinoma), HeLa (cervical adenocarcinoma) and Chang (likely derived from HeLa cells) to sodium arsenite (NaAsO2) for time intervals up to 24 h resulted in a concentration-dependent cytotoxicity and cell death.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Health Perspect. 1999 Jul;107(7):593-7 [10379007.001]
  • [Cites] Cell Cycle. 2003 Jul-Aug;2(4):358-68 [12851490.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 1;172(3):225-32 [11312651.001]
  • [Cites] Mutat Res. 2003 Jan 10;534(1-2):133-43 [12504762.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3445-53 [10910055.001]
  • [Cites] Mol Cell Biol. 1988 Aug;8(8):3556-9 [3062383.001]
  • [Cites] Annu Rev Biochem. 1998;67:425-79 [9759494.001]
  • [Cites] J Cell Physiol. 2002 Jan;190(1):29-37 [11807808.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33968-75 [15178684.001]
  • [Cites] J Biol Chem. 1995 Sep 8;270(36):21176-80 [7673150.001]
  • [Cites] Oncogene. 1999 Jul 29;18(30):4326-35 [10439040.001]
  • [Cites] J Toxicol Environ Health A. 2000 Jan 28;59(2):119-34 [10653439.001]
  • [Cites] J Cell Mol Med. 2001 Jul-Sep;5(3):221-39 [12067482.001]
  • [Cites] Mutat Res. 1997 Jun;386(3):219-28 [9219560.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8960-7 [15604259.001]
  • [Cites] Eur J Biochem. 2000 Feb;267(4):1083-91 [10672017.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2000;19(3):281-6 [10983894.001]
  • [Cites] Science. 1988 Jul 1;241(4861):79-81 [3388020.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Jan 15;186(2):101-9 [12639501.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24776-80 [10811643.001]
  • [Cites] Oncogene. 2000 Jun 15;19(26):3021-31 [10871854.001]
  • [Cites] J Biol Chem. 2005 Jul 1;280(26):25162-9 [15878868.001]
  • [Cites] Mol Cell Biol. 1991 Nov;11(11):5435-45 [1922056.001]
  • [Cites] Cancer Causes Control. 1997 May;8(3):371-85 [9498900.001]
  • [Cites] Cell Death Differ. 2001 Aug;8(8):841-9 [11526437.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1296-300 [7882325.001]
  • [Cites] Br J Cancer. 1992 Nov;66(5):888-92 [1419632.001]
  • [Cites] Toxicol Lett. 2002 Jul 7;133(1):47-57 [12076509.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11414-9 [11150309.001]
  • [Cites] Environ Health Perspect. 2000 May;108(5):393-7 [10811564.001]
  • [Cites] Am J Epidemiol. 1998 Apr 1;147(7):660-9 [9554605.001]
  • [Cites] Oncogene. 2000 Mar 9;19(11):1437-47 [10723135.001]
  • [Cites] J Biol Chem. 1985 May 10;260(9):5486-92 [3988764.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7950-8 [14633726.001]
  • [Cites] Toxicol Lett. 2001 Jul 6;122(3):223-34 [11489357.001]
  • [Cites] Carcinogenesis. 1985 Oct;6(10):1421-6 [3840060.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 1998 Jul-Sep;1(3):199-241 [9644328.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8212-6 [2122455.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1065-70 [8577715.001]
  • [Cites] Anal Chem. 1999 Apr 1;71(7):1408-14 [10204040.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1990-5 [11842186.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):29111-5 [11408474.001]
  • [Cites] EMBO J. 1996 Nov 15;15(22):6269-79 [8947050.001]
  • [Cites] Mol Cell Biol. 1996 Nov;16(11):6573-81 [8887686.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(6):1656-63 [11865045.001]
  • [Cites] Nucleic Acids Res. 1989 Aug 11;17(15):5923-31 [2671936.001]
  • (PMID = 16283521.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Arsenites; 0 / Eukaryotic Initiation Factor-4E; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Sodium Compounds; 0 / Ubiquitin; 136601-57-5 / Cyclin D1; 48OVY2OC72 / sodium arsenite
  •  go-up   go-down


71. Kong CS, Beck AH, Longacre TA: A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas. Am J Surg Pathol; 2010 Jul;34(7):915-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas.
  • Endometrial and endocervical adenocarcinomas may seem histologically identical and it can be difficult to determine primary site of origin based on morphology alone.
  • The TMA consisted of 214 endometrial carcinomas, 33 endocervical adenocarcinomas, and 36 problematic cases.
  • The endometrial and endocervical carcinomas represented usual endometrioid and mucinous types, and special variants (uterine serous carcinoma, uterine clear cell carcinoma, minimal deviation endocervical adenocarcinoma, cervical small cell carcinoma, adenoid basal cell carcinoma, mesonephric carcinoma).
  • Using a script written in R, the diagnostic accuracy of all possible combinations of markers was evaluated and it was shown that a 3 marker panel including vimentin, ER, or PR, and an HPV marker (p16, ProExC, or HPV ISH) is optimal for determining site of origin for usual endometrial and endocervical adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. DNA, Viral / analysis. Endometrial Neoplasms / diagnosis. Papillomaviridae / genetics. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Papillomavirus Infections / diagnosis. Reproducibility of Results. Tissue Array Analysis. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534993.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NLM NIH HHS / LM / T15 LM007033
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral; 0 / Vimentin
  • [Other-IDs] NLM/ NIHMS775595; NLM/ PMC4847142
  •  go-up   go-down


72. Nishio S, Ushijima K, Tsuda N, Takemoto S, Kawano K, Yamaguchi T, Nishida N, Kakuma T, Tsuda H, Kasamatsu T, Sasajima Y, Kage M, Kuwano M, Kamura T: Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma. Cancer Lett; 2008 Jun 8;264(1):36-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma.
  • This study investigated associations of Cap43 expression with angiogenesis and other clinicopathological factors in cervical adenocarcinoma.
  • The clinical records of 100 women who underwent surgery for cervical adenocarcinoma were reviewed retrospectively.
  • Our results suggest that increased expression of Cap43 is associated with angiogenesis and may be a poor prognostic indicator in women with cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / blood supply. Adenocarcinoma / metabolism. Cell Cycle Proteins / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Neovascularization, Pathologic. Uterine Cervical Neoplasms / blood supply. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281151.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / N-myc downstream-regulated gene 1 protein; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


73. Altaf FJ: Cervical cancer screening with pattern of pap smear. Review of multicenter studies. Saudi Med J; 2006 Oct;27(10):1498-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical cancer screening with pattern of pap smear. Review of multicenter studies.
  • OBJECTIVE: To estimate the frequency of abnormal cervical smears and to compare the findings with earlier reported data from Saudi Arabia.
  • The malignant categories were squamous cell carcinoma (0.08%), adenocarcinoma of cervix in situ (0.02%) and invasive (0.04%).
  • Unified national programs for diagnosing cervical precancerous lesions should be established covering different region of the Kingdom to evaluate the magnitude of the problem.
  • [MeSH-major] Papanicolaou Test. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / epidemiology. Vaginal Smears / trends


74. Chang J, Zhang S, Zhou H, Liang JX, Lin ZQ: [Clinical analysis of minimal deviation adenocarcinoma of the cervix: a report of five cases]. Ai Zheng; 2008 Dec;27(12):1310-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of minimal deviation adenocarcinoma of the cervix: a report of five cases].
  • BACKGROUND & OBJECTIVE: The minimal deviation adeno-carcinoma (MDA) of the cervix is a rare disease.
  • This study was to evaluate clinicopathologic features, diagnosis, and treatment of MDA.
  • CONCLUSIONS: Diagnosis of MDA mainly depends on its clinical manifestations and the pathological feature that MDA glands are located deeper than the lower level of normal endocervical glands.
  • [MeSH-major] Adenocarcinoma / therapy. Neoplasm Recurrence, Local. Uterine Cervical Neoplasms / therapy


75. Lange TS, Kim KK, Singh RK, Strongin RM, McCourt CK, Brard L: Iron(III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells. PLoS One; 2008 May 28;3(5):e2303
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iron(III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells.
  • BACKGROUND: In this pioneer study to the biological activity of organometallic compound Iron(III)-salophene (Fe-SP) the specific effects of Fe-SP on viability, morphology, proliferation, and cell-cycle progression on platinum-resistant ovarian cancer cell lines were investigated.
  • METHODOLOGY/PRINCIPAL FINDINGS: Fe-SP displayed selective cytotoxicity against SKOV-3 and OVCAR-3 (ovarian epithelial adenocarcinoma) cell lines at concentrations between 100 nM and 1 microM, while the viability of HeLa cells (epithelial cervix adenocarcinoma) or primary lung or skin fibroblasts was not affected.
  • When intra-peritoneally applied to rats Fe-SP did not show any systemic toxicity at concentrations that in preliminary trials were determined to be chemotherapeutic relevant doses in a rat ovarian cancer cell model.
  • CONCLUSION/SIGNIFICANCE: The present report suggests that Fe-SP is a potent growth-suppressing agent in vitro for cell lines derived from ovarian cancer and a potential therapeutic drug to treat such tumors in vivo.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1998 Aug 28;281(5381):1312-6 [9721091.001]
  • [Cites] J Biol Chem. 1998 Dec 11;273(50):33533-9 [9837934.001]
  • [Cites] Leukemia. 1999 Jul;13(7):1037-45 [10400419.001]
  • [Cites] Nat Cell Biol. 1999 Jul;1(3):E73-9 [10559915.001]
  • [Cites] J Clin Invest. 1999 Dec;104(12):1645-53 [10606615.001]
  • [Cites] Nucleic Acids Res. 1999 Nov 1;27(21):4160-6 [10518606.001]
  • [Cites] J Med Chem. 2004 Nov 18;47(24):5837-46 [15537341.001]
  • [Cites] Free Radic Biol Med. 2005 Jan 1;38(1):58-69 [15589372.001]
  • [Cites] Biochem Pharmacol. 2005 Apr 1;69(7):1009-39 [15763539.001]
  • [Cites] J Inorg Biochem. 2005 Jul;99(7):1433-40 [15878622.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9756-60 [16785432.001]
  • [Cites] Arch Pharm (Weinheim). 2007 Mar;340(3):117-26 [17315259.001]
  • [Cites] Biochem Pharmacol. 2007 Jun 30;74(1):118-30 [17475222.001]
  • [Cites] Bioorg Med Chem Lett. 2007 Jul 1;17(13):3774-7 [17466518.001]
  • [Cites] Chem Biol Drug Des. 2007 Oct;70(4):302-10 [17937776.001]
  • [Cites] Genes Dev. 2007 Nov 15;21(22):2908-22 [18006686.001]
  • [Cites] J Inorg Biochem. 2008 Apr;102(4):740-7 [18180039.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):240-9 [18329084.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):153-83 [11294822.001]
  • [Cites] J Cell Biol. 2002 Apr 29;157(3):441-53 [11980919.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Jun;42(3):213-5 [12050015.001]
  • [Cites] J Med Chem. 2002 Sep 26;45(20):4549-58 [12238934.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):160-2 [14522248.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Feb;4(1):65-75 [14965268.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2774-84 [15077141.001]
  • [Cites] Int J Gynecol Cancer. 2004 Sep-Oct;14(5):772-8 [15361183.001]
  • [Cites] Arch Biochem Biophys. 1994 Nov 15;315(1):74-81 [7979408.001]
  • [Cites] Eur J Clin Pharmacol. 1994;47(1):1-16 [7988618.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1821-8 [7997877.001]
  • [Cites] Curr Opin Cell Biol. 1995 Jun;7(3):337-43 [7662363.001]
  • [Cites] Bioorg Med Chem. 1996 Aug;4(8):1185-96 [8879539.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1659-64 [8939847.001]
  • [Cites] Bioconjug Chem. 1997 Nov-Dec;8(6):789-92 [9404650.001]
  • [Cites] Bioconjug Chem. 1997 Nov-Dec;8(6):798-812 [9404652.001]
  • [Cites] Toxicology. 1997 Dec 31;124(3):179-92 [9482120.001]
  • [ErratumIn] PLoS ONE. 2008;3(7). doi: 10.1371/annotation/d97d24fc-aa07-40fd-88b2-6b2e050ddb31
  • (PMID = 18509533.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD043447; United States / NCRR NIH HHS / RR / P20 RR018728; United States / NCRR NIH HHS / RR / 1-P20RR018728
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ferric Compounds; 0 / Iron(III)-salophene; 49DFR088MY / Platinum
  • [Other-IDs] NLM/ PMC2386551
  •  go-up   go-down


76. Goyal M, Kodandapani S, Sharanabasappa SN, Palanki SD: Mesothelial cell inclusions mimicking adenocarcinoma in cervical lymph nodes in association with chylous effusion. Indian J Med Paediatr Oncol; 2010 Apr;31(2):62-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelial cell inclusions mimicking adenocarcinoma in cervical lymph nodes in association with chylous effusion.
  • Mesothelial cell inclusions in lymph nodes are of rare occurrence and can be mistaken as metastatic adenocarcinomas, mesothelioma or sinus histiocytosis.
  • We report a case of benign mesothelial cell inclusions in cervical lymph nodes, which was associated with chylous effusion, and immunohistochemistry revealed unusual weak cytoplasmic epithelial membrane antigen positivity in the cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1999 Oct;23(10):1264-9 [10524528.001]
  • [Cites] J Postgrad Med. 2008 Jul-Sep;54(3):230-1 [18626177.001]
  • [Cites] Histopathology. 1998 Dec;33(6):570-5 [9870153.001]
  • [Cites] Diagn Cytopathol. 1995 Jul;13(1):3-7 [7587872.001]
  • [Cites] Hum Pathol. 1998 Apr;29(4):339-46 [9563782.001]
  • [Cites] Am J Clin Pathol. 1990 Jun;93(6):741-8 [2161177.001]
  • (PMID = 21209767.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2970937
  • [Keywords] NOTNLM ; Adenocarcinoma / chylous effusion / epithelial membrane antigen / mesothelial cell inclusions
  •  go-up   go-down


77. Dunton CJ: Management of atypical glandular cells and adenocarcinoma in situ. Obstet Gynecol Clin North Am; 2008 Dec;35(4):623-32; ix
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of atypical glandular cells and adenocarcinoma in situ.
  • Glandular abnormalities of the cervix remain a difficult clinical problem.
  • It also discusses the diagnosis of associated endometrial lesions and the use of human papillomavirus DNA testing in the management of glandular lesions of the lower genital tract.
  • [MeSH-major] Adenocarcinoma / therapy. Cervical Intraepithelial Neoplasia / therapy. Pregnancy Complications, Neoplastic / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. Cervix Uteri / cytology. Cervix Uteri / pathology. DNA, Viral / analysis. Female. Humans. Middle Aged. Papillomaviridae / isolation & purification. Papillomavirus Infections / complications. Papillomavirus Infections / pathology. Papillomavirus Infections / therapy. Postmenopause. Pregnancy. Vaginal Smears. Young Adult


78. Li WX, Zheng QQ, Wang P, Li YQ, Chen GH: [Fourier transform infrared spectroscopy study on normal and malignant tissues of cervix]. Guang Pu Xue Yu Guang Pu Fen Xi; 2006 Oct;26(10):1833-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fourier transform infrared spectroscopy study on normal and malignant tissues of cervix].
  • Fourier transform infrared spectroscopy (FTIR) was used to investigate 35 cervical tissues , including 17 squamous cell carcinoma of cervical samples, and 5 adenocarcinoma of cervical samples, 13 normal cervical samples.
  • The results show that there are 18 spectral bands with highly appearance percentage(>80%) in these three types of tissues, and these spectral bands may be the characteristic infrared spectra bands for cervical tissues; Some of relative absorbance ratios are statistically significant (p < 0.05) among these three types of tissues.
  • The utilization of FTIR spectra in cervical tissues is expected to be a hopeful method in cervical cancer screening and clinical diagnosis in the future.
  • [MeSH-major] Cervix Uteri / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Pregnancy. Spectroscopy, Fourier Transform Infrared / methods. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology


79. An HJ, Kim KR, Kim IS, Kim DW, Park MH, Park IA, Suh KS, Seo EJ, Sung SH, Sohn JH, Yoon HK, Chang ED, Cho HI, Han JY, Hong SR, Ahn GH: Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study. Mod Pathol; 2005 Apr;18(4):528-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study.
  • The role of human papilloma virus (HPV) infection in the development of cervical carcinoma is well established, however, the prevalence of HPV DNA in cervical adenocarcinoma varies from study to study.
  • It appears to be caused by a number of factors, one of which is that cervical adenocarcinomas comprise a heterogeneous group of multiple subtypes.
  • To clarify the impact of HPV infection on the development of cervical adenocarcinoma with diverse histological subtypes, we performed a population-based study in Korean women from 15 different institutes for the status of HPV infection in adenocarcinoma of uterine cervix.
  • A total of 432 cervical adenocarcinomas from 1997 to 2001 were reviewed and classified according to the modified WHO classification.
  • The overall prevalence of HPV infection in cervical adenocarcinoma was 90%.
  • The infection of HPV 16 and/or HPV 18 accounted for 78% of HPV-positive adenocarcinomas.
  • The HPV DNA was rarely detected in minimal deviation adenocarcinoma.
  • In conclusion, HPV infection, mostly HPV 16 and HPV 18, is highly associated with most of the cervical adenocarcinomas, whereas endometrioid and villoglandular type have a different pattern of HPV infection status.
  • Minimal deviation adenocarcinoma does not seem to be related with HPV infection.
  • [MeSH-major] Adenocarcinoma / pathology. DNA, Viral / genetics. Papillomaviridae / genetics. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15502807.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


80. Tarkkanen J, Auvinen E, Nieminen P, Malmi R, Vartiainen J, Timonen T, Laurila P, Räisänen I, Unnerus HA, Sakki A, Mattila P, Van Den Brule AV, Tapper AM: HPV DNA testing as an adjunct in the management of patients with low grade cytological lesions in Finland. Acta Obstet Gynecol Scand; 2007;86(3):367-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 5/97 (5.2%) high grade lesions, which were HC2-negative but pap-positive, including 1 cervical adenocarcinoma in situ.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / diagnosis. DNA, Viral / analysis. Papillomaviridae / isolation & purification. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17364315.001).
  • [ISSN] 0001-6349
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


81. Sullivan LM, Smolkin ME, Frierson HF Jr, Galgano MT: Comprehensive evaluation of CDX2 in invasive cervical adenocarcinomas: immunopositivity in the absence of overt colorectal morphology. Am J Surg Pathol; 2008 Nov;32(11):1608-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive evaluation of CDX2 in invasive cervical adenocarcinomas: immunopositivity in the absence of overt colorectal morphology.
  • In addition to staining adenocarcinomas of the alimentary system, studies have demonstrated CDX2 positivity in a percentage of ovarian mucinous and endometrioid tumors, carcinoids, and some adenocarcinomas of other sites such as the urinary bladder, prostate, lung, and pancreas.
  • However, CDX2 immunostaining in cervical adenocarcinomas has not been examined in detail with comparison to important clinicopathologic characteristics including histopathologic subtype, tumor stage, and patient follow-up.
  • In this study of 81 invasive cervical adenocarcinomas, 24 of the cases (30%) demonstrated nuclear positivity.
  • Our results indicate that cervical adenocarcinomas can show nuclear immunopositivity for CDX2 even in the absence of overt morphologic features of colorectal differentiation.
  • The frequency and pattern of CDX2 staining in the more common histologic subtypes of cervical adenocarcinoma (endocervical usual-type and endometrioid) is parallel to that which is seen for adenocarcinomas of the upper gastrointestinal tract and pancreaticobiliary system.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Intestine, Large / pathology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753946.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


82. Luyten A, Scherbring S, Reinecke-Lüthge A, Braun BE, Pietralla M, Theiler K, Petry KU: Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years. J Clin Virol; 2009 Nov;46 Suppl 3:S5-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
  • BACKGROUND: Currently, the German cervical cancer screening program encompasses an annual cytological Papanicolaou (Pap) smear.
  • However, primary screening for cervical cancer using human papillomavirus (HPV) DNA testing detects cervical pre-cancerous lesions with a significantly higher sensitivity than the Pap smear-based cytology.
  • OBJECTIVES: In order to develop viable modalities for primary cervical screening incorporating DNA testing for high-risk (HR) types of HPV, we started a pilot project in the city of Wolfsburg, Germany, in February 2006.
  • There were 417 (2.48%) women referred for colposcopy, 104 of whom were diagnosed with cervical intraepithelial neoplasia (CIN) 3 or worse, including 8 invasive cancers and 8 adenocarcinoma in situ (ACIS).
  • CONCLUSIONS: The presented risk-adapted Wolfsburg Cervical Cancer Prevention Project ("Wolfsburg Model") has been shown to be effective and feasible in identifying women at risk and for avoiding unnecessary procedures for those who are double negative, thus allowing longer screening intervals and cost savings.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / diagnosis. Mass Screening / methods. Papillomavirus Infections / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Alphapapillomavirus / genetics. Alphapapillomavirus / isolation & purification. Cervix Uteri / pathology. Cervix Uteri / virology. Colposcopy. DNA, Viral / genetics. DNA, Viral / isolation & purification. Early Detection of Cancer / economics. Early Detection of Cancer / methods. Female. Germany. Humans. Middle Aged. Papanicolaou Test. Pilot Projects. Risk. Time Factors. Vaginal Smears


83. Yoo KJ, Lee HJ, Lee H, Lee KY, Lee SH, Chung HM, Baek KH: Expression and functional analyses of mHAUSP regulating apoptosis of cervical adenocarcinoma cells. Int J Oncol; 2005 Jul;27(1):97-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and functional analyses of mHAUSP regulating apoptosis of cervical adenocarcinoma cells.
  • [MeSH-major] Apoptosis. Endopeptidases / biosynthesis. Endopeptidases / physiology. Gene Expression Regulation, Developmental. Gene Expression Regulation, Neoplastic. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology


84. Chen Y, Xu H, Zhang Q, Li Y, Wang D, Liang Z: A fertility-preserving option in early cervical carcinoma: laparoscopy-assisted vaginal radical trachelectomy and pelvic lymphadenectomy. Eur J Obstet Gynecol Reprod Biol; 2008 Jan;136(1):90-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A fertility-preserving option in early cervical carcinoma: laparoscopy-assisted vaginal radical trachelectomy and pelvic lymphadenectomy.
  • OBJECTIVE: Laparoscopic vaginal radical trachelectomy is a fertility-preserving alternative to radical hysterectomy or chemoradiation in young women with stage IA2 to IB cervical cancers.
  • The aim of this study is to describe the feasibility and outcome of laparoscopic radical vaginal trachelectomy and pelvic lymphadenectomy in women treated with early cervical cancers who wish to maintain fertility.
  • Patients were selected for this treatment on the basis of favorable cervical tumors and a desire to maintain fertility.
  • CONCLUSIONS: Laparoscopy-assisted radical vaginal trachelectomy is an adequate treatment, with its minimally invasive procedure and shorter recovery time, for early-stage cervical cancer in women who wish to preserve fertility.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Gynecologic Surgical Procedures / methods. Lymph Node Excision. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Cervix Uteri / surgery. Female. Fertility. Follow-Up Studies. Humans. Laparoscopy. Neoplasm Staging. Pelvis. Pregnancy. Vagina / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17137704.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


85. Alrawi SJ, Winston J, Tan D, Gibbs J, Loree TR, Hicks W, Rigual N, Lorè JM Jr: Primary adenocarcinoma of cervical esophagus. J Exp Clin Cancer Res; 2005 Jun;24(2):325-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of cervical esophagus.
  • Most upper esophageal malignancies are squamous cell carcinomas, rarely adenocarcinomas arising from Barrett's esophagus and very rarely adenocarcinomas from heterotopic gastric mucosa without evidence of Barrett's especially in the cervical part of the esophagus.
  • We report a case of adenocarcinoma of the polypoid type in the upper esophagus (cervical esophagus) arising from ectopic gastric mucosa, in a 60 year-old man who presented with progressive dysphagia.
  • Accurate diagnosis by esophagogram revealed a large mass in the cervical esophagus; CAT scan showed intraluminal mass at the level of thoracic inlet, esophagogastroscopy showed a fleshy polyp (3.2cm x 3.0cm) at 20 cm from the incisors with a biopsy confirming moderately differentiated adenocarcinoma with no evidence of Barrett's esophagus.
  • Through a left cervical approach and resection of medial third of clavicle, the tumor was removed by partial esophagectomy followed by lymph node dissection, and proved to be T1NOMO, stage I (AJCC staging 6th ed.).
  • It seems this tumor has a much better prognosis than adenocarcinomas arising from Barrett's.
  • [MeSH-major] Adenocarcinoma / diagnosis. Esophageal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110768.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


86. Ovanin-Rakić A, Mahovlić V, Audy-Jurković S, Barisić A, Skopljanac-Macina L, Jurić D, Rajhvajn S, Ilić-Forko J, Babić D, Folnović D, Kani D: Cytology of cervical intraepithelial glandular lesions. Coll Antropol; 2010 Jun;34(2):401-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytology of cervical intraepithelial glandular lesions.
  • Cytological criteria for the identification of glandular intraepithelial lesions (GIL) have not yet been fully described, especially for the precursors of adenocarcinoma in situ (AIS), thus these lesions may frequently remain unrecognized.
  • The aim of the study was to achieve the most appropriate cytologic diagnosis of intraepithelial lesions of endocervical columnar epithelium, analyzing the cytology findings in patients with histologically verified AIS and GIL (I, II).
  • The value of cytology in the detection and differential diagnosis was assessed in 123 patients with definitive histologic diagnosis of glandular lesions (AIS, n = 13; GIL I, n = 11; and GIL II, n = 7), and glandular lesions associated with squamous component (AIS associated with cervical intraepithelial neoplasia (CIN) or invasive squamous cell carcinoma (SCC), n = 58; GIL I or GIL II associated with CIN, n = 28; and GIL associated with microinvasive squamous carcinoma (MIC), n = 6).
  • In terms of differential diagnosis, cytology showed higher accuracy in predicting lesion severity vs. type of epithelial alteration (75.6% vs. 55.3%) and abnormalities of columnar epithelium (95.7%; vs. 74.2%).
  • Continuous improvement in cervical specimens and cytodiagnostic skills, better understanding of intraepithelial adenocarcinoma and precursors, and their inclusion in the classification of cytologic and histologic findings are expected to upgrade the detection of these lesions, and to reduce the invasive cervical adenocarcinoma morbidity and mortality.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Humans. Neoplasm Invasiveness. Neoplasm Staging. Vaginal Smears

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698109.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


87. Elishaev E, Gilks CB, Miller D, Srodon M, Kurman RJ, Ronnett BM: Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol; 2005 Mar;29(3):281-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms.
  • The vast majority of endocervical adenocarcinomas are high-risk human papillomavirus (HPV)-related neoplasms, characterized by p16 expression and frequent loss of hormone receptor expression, which infrequently metastasize to the ovaries.
  • We report 10 cases of endocervical adenocarcinomas with ovarian metastases in which the ovarian tumors simulated primary ovarian surface epithelial neoplasms.
  • The ovarian metastases presented concurrently with the primary endocervical tumors in 5 cases, subsequent to the endocervical tumors in 3 cases, and prior to diagnosis of the endocervical tumors in 2 cases.
  • The endocervical tumors ranged in size from microscopic foci to 3 cm, with depth of invasion ranging from 0.2 to 1.5 cm; in 2 cases, the invasive foci qualified as microinvasive according to Federation Internationale de Gynecologie et d'Obstetrique staging criteria for cervical carcinoma.
  • Adenocarcinoma in situ was identified in all tumors.
  • Two of the minimally invasive endocervical tumors were initially interpreted as adenocarcinoma in situ and not recognized as unequivocally invasive even when evaluated in conjunction with the histologically identical ovarian tumors.
  • HPV DNA detection in the ovarian tumors of 2 patients without known cervical disease led to discovery of occult cervical adenocarcinomas in those patients.
  • Endocervical adenocarcinomas, including some qualifying as microinvasive, can metastasize to the ovaries and simulate primary ovarian surface epithelial neoplasms.
  • The presence of HPV DNA in these ovarian tumors confirms that they are metastatic endocervical adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / secondary. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / secondary. Uterine Cervical Neoplasms / pathology


88. Longatto Filho A, Albergaria A, Paredes J, Moreira MA, Milanezi F, Schmitt FC: P-cadherin expression in glandular lesions of the uterine cervix detected by liquid-based cytology. Cytopathology; 2005 Apr;16(2):88-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P-cadherin expression in glandular lesions of the uterine cervix detected by liquid-based cytology.
  • OBJECTIVE: To study P-cadherin aberrant expression as a possible marker for cervical adenocarcinomas in cytological samples.
  • METHODS: We studied P-cadherin immunoexpression in liquid-based cervical cytology samples of biopsy-proven cervical lesions.
  • RESULTS: We found a statistically significant correlation between P-cadherin expression and a cytological diagnosis of malignancy, either glandular or squamous (P < 0.0001).
  • CONCLUSIONS: We concluded that P-cadherin can be used to discriminate between malignant and benign cervical cytological specimens, but not to discriminate glandular from squamous lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Cadherins / biosynthesis. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15787651.001).
  • [ISSN] 0956-5507
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins
  •  go-up   go-down


89. Seamon LG, Richardson DL, Pierce M, O'Malley DM, Griffin S, Cohn DE: Local correction of extreme stomal prolapse following transverse loop colostomy. Gynecol Oncol; 2008 Dec;111(3):549-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: A 57 year-old patient with stage IVB adenocarcinoma of the cervix underwent a transverse loop colostomy for palliation of a rectovaginal fistula.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / surgery. Female. Humans. Middle Aged. Palliative Care. Prolapse. Rectovaginal Fistula / complications. Rectovaginal Fistula / surgery. Uterine Cervical Neoplasms / complications. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18304621.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Morelva Tde M, Antonio LB: Immunohistochemical expression of ubiquitin and telomerase in cervical cancer. Virchows Arch; 2009 Sep;455(3):235-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of ubiquitin and telomerase in cervical cancer.
  • Ubiquitin and telomerase immunohistochemical expression patterns in cervical cancer were compared with normal cervical tissue samples.
  • Eighty-one cervical cancer cases and 22 normal exo-endocervical tissue were examined with polyclonal antibody for ubiquitin and 44G12 clone for telomerase using tissue microarrays.
  • The most frequent histological types were moderately differentiated epidermoid carcinoma (43.5%), according to the degree of differentiation, and endocervical adenocarcinoma (42.1%).
  • Immunohistochemical findings were as follows: 98.7% of cervical cancers showed immunoexpression for ubiquitin and 52.6% for telomerase.
  • There was no significant difference in biomarker expression at different histological types of tumors, although telomerase was less expressed in endocervical adenocarcinoma.
  • Our findings confirm that abnormal immunoexpression pattern of ubiquitin and telomerase is common in HPV-positive cervical cancer, indicating the existence of an intense degradation of proteins, subsequent cellular immortalization and maintenance of the malignant phenotype.
  • [MeSH-major] Biomarkers, Tumor / analysis. Telomerase / analysis. Ubiquitin / analysis. Uterine Cervical Neoplasms / chemistry
  • [MeSH-minor] Adult. Aged. Cervix Uteri / chemistry. Female. Humans. Immunohistochemistry. Middle Aged. Papillomaviridae / isolation & purification. Tissue Array Analysis

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest Clin. 2005 Sep;46(3):255-63 [16152781.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5201-7 [12910257.001]
  • [Cites] Zentralbl Gynakol. 2001 Apr;123(4):186-91 [11370525.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1558-61 [9537264.001]
  • [Cites] Pharmacol Ther. 1998 Jun;78(3):129-39 [9690814.001]
  • [Cites] J Virol. 2001 May;75(9):4467-72 [11287602.001]
  • [Cites] J Virol. 2001 Aug;75(15):7198-201 [11435602.001]
  • [Cites] Semin Cancer Biol. 2003 Feb;13(1):59-67 [12507557.001]
  • [Cites] N Engl J Med. 1996 Dec 19;335(25):1897-905 [8948566.001]
  • [Cites] J Virol. 2001 Jun;75(12):5559-66 [11356963.001]
  • [Cites] J Clin Pathol. 2003 Jan;56(1):31-5 [12499429.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Chin Med J (Engl). 2004 Feb;117(2):202-6 [14975203.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4620-4 [8840974.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/42-51 [16950017.001]
  • [Cites] Yonsei Med J. 2005 Oct 31;46(5):597-613 [16259056.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98 (3):1218-23 [11158620.001]
  • [Cites] Oncol Rep. 2002 Jan-Feb;9(1):43-9 [11748453.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):664-73 [11850794.001]
  • [Cites] Hum Pathol. 2004 Apr;35(4):396-402 [15116318.001]
  • [Cites] J Virol. 2001 Aug;75(16):7583-91 [11462030.001]
  • [Cites] Gynecol Oncol. 1998 Feb;68(2):145-9 [9514809.001]
  • [Cites] Am J Pathol. 1997 Jul;151(1):25-31 [9212727.001]
  • [Cites] J Virol. 2000 Jul;74(14 ):6408-17 [10864652.001]
  • [Cites] Eur J Cancer. 1997 Apr;33(5):787-91 [9282118.001]
  • [Cites] J Mol Med (Berl). 1997 Jan;75(1):5-17 [9020379.001]
  • [Cites] Histochem Cell Biol. 2004 May;121(5):391-7 [15138842.001]
  • [Cites] Am J Clin Pathol. 1998 Feb;109(2):153-62 [9583886.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):690-8 [10793105.001]
  • [Cites] FASEB J. 1997 Nov;11(13):1067-75 [9367342.001]
  • [Cites] J Clin Pathol. 2005 Sep;58(9):911-4 [16126869.001]
  • [Cites] Br J Cancer. 2007 Apr 10;96(7):1020-4 [17353922.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):859-67 [12937127.001]
  • [Cites] J Biol Chem. 1997 Nov 28;272(48):30135-40 [9374493.001]
  • [Cites] EMBO J. 2005 Oct 5;24(19):3353-9 [16148945.001]
  • [Cites] J Immunol. 2001 Apr 15;166(8):4826-30 [11290757.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92 (7):2563-7 [7708685.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8211-6 [12821782.001]
  • [Cites] Diagn Cytopathol. 2006 Nov;34(11):739-48 [17041957.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1319-27 [9529024.001]
  • (PMID = 19680685.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ubiquitin; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


91. Bao YP, Li N, Smith JS, Qiao YL: Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis. Int J STD AIDS; 2008 Feb;19(2):106-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis.
  • The aim of the study was to determine human papillomavirus (HPV) type-distribution in the cervix of Chinese women, and to estimate the potential future impact of HPV prophylactic vaccines for cervical cancer prevention in China.
  • A total of 32 studies using polymerase chain reaction for HPV detection were included in the meta-analysis, including 2844 invasive cervical cancer (ICC), 820 high-grade squamous intraepithelial lesions (HSIL), 432 low-grade squamous intraepithelial lesions (LSIL) and 2902 women with normal cytology/histology.
  • The overall and type-specific HPV prevalence of 18 HPV types (HPV 6, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 70, 73 and 82 of different cervical stages) were estimated.
  • HPV 16 was the predominant type in all cervical stages.
  • [MeSH-major] Cervix Uteri / virology. Papillomaviridae / classification. Papillomaviridae / isolation & purification. Papillomavirus Infections / epidemiology. Uterine Cervical Diseases / virology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / prevention & control. Adenocarcinoma / virology. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / prevention & control. Carcinoma, Adenosquamous / virology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / prevention & control. Carcinoma, Squamous Cell / virology. China / epidemiology. DNA, Viral / genetics. Female. Humans. Papillomavirus Vaccines / immunology


92. Pak SC, Martens M, Bekkers R, Crandon AJ, Land R, Nicklin JL, Perrin LC, Obermair A: Pap smear screening history of women with squamous cell carcinoma and adenocarcinoma of the cervix. Aust N Z J Obstet Gynaecol; 2007 Dec;47(6):504-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pap smear screening history of women with squamous cell carcinoma and adenocarcinoma of the cervix.
  • BACKGROUND: Since the introduction of the Pap smear screening, the incidence of squamous cell carcinoma (SCC) has decreased significantly, but the incidence of adenocarcinoma (AC) relative to SCC has increased.
  • AIM: To compare the Pap smear history of patients with AC and SCC of the cervix.
  • METHODS: Patients for the study were identified from the database of Queensland Centre for Gynaecological Cancer.
  • Patients with AC and SCC were matched for age at diagnosis and International Federation of Gynecology and Obstetrics stage.
  • Data were collected upon the histological type of cancer, result of the most recent Pap smear, date and result of the Pap smear prior to the most recent Pap smear and symptoms.
  • The time between the most recent Pap smear and the diagnosis of cervical cancer was significantly shorter for patients with AC (P=0.01).
  • Thus, Pap smear prior to a diagnosis of AC is more likely than SCC false-negative and therefore not indicative of cervical cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Papanicolaou Test. Uterine Cervical Neoplasms / epidemiology. Vaginal Smears / utilization


93. Reimers LL, Anderson WF, Rosenberg PS, Henson DE, Castle PE: Etiologic heterogeneity for cervical carcinoma by histopathologic type, using comparative age-period-cohort models. Cancer Epidemiol Biomarkers Prev; 2009 Mar;18(3):792-800
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etiologic heterogeneity for cervical carcinoma by histopathologic type, using comparative age-period-cohort models.
  • BACKGROUND: Cervical carcinomas comprise two main histopathologic types, squamous cell carcinomas and adenocarcinomas.
  • METHODS: To assess potential etiologic heterogeneity of cervical cancer by histopathologic type, we examined invasive squamous cell carcinomas and adenocarcinoma cervical cancer incidence rates in the National Cancer Institute's Surveillance, Epidemiology, and End Results database.
  • RESULTS: Squamous cell tumors (n=25,219) were nearly 5-fold more common than adenocarcinomas (n=5,451).
  • Age-adjusted incidence trends decreased for squamous cell carcinomas but increased for adenocarcinomas.
  • Cross-sectional age-specific incidence rates increased more rapidly for squamous cell carcinomas than adenocarcinomas in adolescents and young adults then leveled off for both types.
  • For squamous cell carcinoma, the APC "fitted" age-at-onset rate curve peaked before age 40 years then declined; for adenocarcinoma, the fitted curve increased rapidly until age 40 years then rose more slowly.
  • CONCLUSIONS: Despite the necessary role of HPV infection in both squamous cell carcinomas and adenocarcinomas of the cervix, secular trends and age-related natural histories differed for the two tumor types, consistent with etiologic heterogeneity.
  • Future analytic and clinical studies should consider the interaction (effect modification) of HPV infection and other cervical carcinoma risk factors by histopathologic type, time, and age.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / classification. Carcinoma, Squamous Cell / epidemiology. Papillomavirus Infections / epidemiology. Uterine Cervical Neoplasms / classification. Uterine Cervical Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19258470.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


94. Kovács A, Vasas A, Forgo P, Réthy B, Zupkó I, Hohmann J: Xanthanolides with antitumour activity from Xanthium italicum. Z Naturforsch C; 2009 May-Jun;64(5-6):343-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The isolated compounds 1-4 were evaluated for their antiproliferative activities, and were demonstrated to exert significant cell growth inhibitory activity against human cervix adenocarcinoma (HeLa), skin carcinoma (A431), and breast adenocarcinoma (MCF7) cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19678536.001).
  • [ISSN] 0939-5075
  • [Journal-full-title] Zeitschrift für Naturforschung. C, Journal of biosciences
  • [ISO-abbreviation] Z. Naturforsch., C, J. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Plant Extracts
  •  go-up   go-down


95. Connolly TP, Evans AC: Atypical Papanicolaou smear in pregnancy. Clin Med Res; 2005 Feb;3(1):13-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Atypical glandular cells (AGC) in Papanicolaou (Pap) smears can be associated with premalignant and malignant cervical and endometrial lesions.
  • Positive diagnosis of endocervical adenocarcinoma in situ resulted in a risk-informed decision to proceed with a cold knife conization of the cervix.
  • Final pathology showed complete resection of the lesion with negative margins and an additional area of squamous dysplasia (cervical intraepithelial neoplasia, grade II to III).
  • [MeSH-major] Carcinoma in Situ / diagnosis. Cervix Uteri / pathology. Papanicolaou Test. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Adult. Biopsy. Cervical Intraepithelial Neoplasia / diagnosis. Female. Humans. Pregnancy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / surgery


96. Dugalic V, Gojnic M, Brankovic M, Stojanovic I, Ser F, Zizic V: Bone metastasis arising from a polyp of the cervix as the first symptom in generalized multi-organ adenocarcinoma. Eur J Gynaecol Oncol; 2010;31(5):593-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone metastasis arising from a polyp of the cervix as the first symptom in generalized multi-organ adenocarcinoma.
  • After two vaginal deliveries without any reported difficulties, the patient had no intermenstrual bleeding, postcoital bleeding, leucorrhea or hypermenorrhea, abnormal vaginal bleeding, or postmenstrual bleeding, except during the past five-year period when a polyp-like change in the cervix was found.
  • During Werthaim-Meigs surgery, four positive glandules and cervical adenocarcinoma Stage II were found.
  • Unfortunately, considering the changes in the tissue of the colon and cervix, we considered the condition to be "generalized" adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / pathology. Uterine Cervical Neoplasms / pathology


97. Dainty LA, Krivak TC, Webb JC, Zahn CM, Elkas JC, Chernofsky MR, Rose GS, Maxwell GL: Diffuse laminar endocervical glandular hyperplasia: a case report. Int J Gynecol Cancer; 2009 Aug;19(6):1091-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: We present a 22-year-old woman referred to our gynecologic oncology service with a 2.0 x 4.0-cm exophytic cervical mass.
  • Colposcopic-directed cervical biopsies were diagnosed as adenocarcinoma, suggestive of minimal deviation adenocarcinoma.
  • CONCLUSIONS: Diffuse laminar endocervical glandular hyperplasia is an uncommon histological type of pseudoneoplastic glandular lesions that may be found in the cervix, and this entity should be considered in the differential diagnosis of a potentially malignant endocervical glandular lesion.
  • [MeSH-major] Cervix Uteri / pathology. Neoplasms, Glandular and Epithelial / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / pathology. Postpartum Period. Precancerous Conditions / diagnosis. Young Adult


98. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M: Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol; 2006 Aug;37(8):1000-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy.
  • In tumors of the female genital tract, L1 was detected in adenocarcinomas of the cervix and fallopian tubes, in addition to ovarian and endometrial carcinomas.
  • Nongynecological tumors expressing L1 comprised malignant melanoma, colon adenocarcinoma positive to chromogranin, clear-cell adenocarcinoma of the urinary bladder, pheochromocytoma, small cell lung carcinoma, and tumors of the nervous system.
  • L1 was absent in breast carcinoma, gastrointestinal tract carcinomas, gastrointestinal carcinoids, renal clear-cell carcinomas, prostate adenocarcinomas, and mesotheliomas.
  • Our results suggest that L1 expression in tumors is not ubiquitous but restricted to certain subtypes and may be a helpful molecular marker for differential diagnosis and target for antibody-based therapy.
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Cell Line, Tumor. Diagnosis, Differential. Female. Fluorescent Antibody Technique, Direct. GPI-Linked Proteins. Humans. Immunoenzyme Techniques. Male. Neutrophils / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16867862.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD177 protein, human; 0 / GPI-Linked Proteins; 0 / Isoantigens; 0 / Membrane Glycoproteins; 0 / Receptors, Cell Surface
  •  go-up   go-down


99. Luo CF, Hong HL, Lu YL, Wang H, Liu MQ: [Expressions of bFGF and PTEN in cervical carcinoma and their clinical significance]. Zhonghua Zhong Liu Za Zhi; 2010 Jul;32(7):533-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of bFGF and PTEN in cervical carcinoma and their clinical significance].
  • OBJECTIVE: To investigate the expressions of bFGF and PTEN in cervical carcinoma and their clinical significance.
  • METHODS: Tissue microarray technique and immunohistochemistry SP method were used to detect the expressions of bFGF and PTEN in 143 cases of invasive carcinoma of cervix (ICC) and 20 cases of normal cervical epithelium remote from tumor (NCE).
  • The relationship between the expressions of bFGF and PTEN in ICC and some factors relating to clinical pathology of cervical carcinoma such as histopathological grading, lymph node metastasis, stroma involvement and FIGO staging were analyzed.
  • CONCLUSION: The overexpression of bFGF and underexpression of PTEN are closely related to the invasion and growth of cervical carcinoma.
  • Detection of the expression of both bFGF and PTEN may be of value in further understanding the biological behavior and predicting the prognosis of cervical carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Fibroblast Growth Factor 2 / metabolism. PTEN Phosphohydrolase / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Cervix Uteri / cytology. Cervix Uteri / metabolism. Epithelium / metabolism. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21029699.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 103107-01-3 / Fibroblast Growth Factor 2; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


100. Rodríguez-Sastre MA, González-Maya L, Delgado R, Lizano M, Tsubaki G, Mohar A, García-Carrancá A: Abnormal distribution of E-cadherin and beta-catenin in different histologic types of cancer of the uterine cervix. Gynecol Oncol; 2005 May;97(2):330-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal distribution of E-cadherin and beta-catenin in different histologic types of cancer of the uterine cervix.
  • OBJECTIVE: The goal of this study was to analyze the cellular distribution and possible alterations of beta-catenin and E-cadherin proteins in different histologic types of uterine cervical cancer and precursor lesions, compared to normal controls.
  • METHODS: We performed an immunochemical staining analysis of the cellular distribution of beta-catenin and E-cadherin proteins in biopsy samples from 20 normal exocervical squamous epithelium, 43 premalignant lesions, and a large series of 126 invasive tumors of different histologic types that included 68 squamous carcinomas, 31 adenosquamous carcinomas, and 27 adenocarcinomas.
  • We found no differences in the distribution of E-cadherin between adenocarcinomas compared with control samples.
  • CONCLUSION: Our findings indicate that cellular alterations of both beta-catenin and E-cadherin are frequent in tumors of the uterine cervix of different histologic types, and support a role for these proteins in cervical cancer development.
  • [MeSH-major] Cadherins / metabolism. Cytoskeletal Proteins / metabolism. Trans-Activators / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cervix Uteri / metabolism. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. beta Catenin






Advertisement